US20150342761A1 - Device for in vivo delivery of bioactive agents and method of manufacture thereof - Google Patents
Device for in vivo delivery of bioactive agents and method of manufacture thereof Download PDFInfo
- Publication number
- US20150342761A1 US20150342761A1 US14/825,526 US201514825526A US2015342761A1 US 20150342761 A1 US20150342761 A1 US 20150342761A1 US 201514825526 A US201514825526 A US 201514825526A US 2015342761 A1 US2015342761 A1 US 2015342761A1
- Authority
- US
- United States
- Prior art keywords
- layer
- cantilever
- members
- cover members
- biocompatible material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/07—Endoradiosondes
- A61B5/076—Permanent implantations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/6862—Stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6867—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive specially adapted to be attached or implanted in a specific body part
- A61B5/6876—Blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
- A61B5/02055—Simultaneously evaluating both cardiovascular condition and temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/0215—Measuring pressure in heart or blood vessels by means inserted into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
- A61F2002/91541—Adjacent bands are arranged out of phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91558—Adjacent bands being connected to each other connected peak to peak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0001—Means for transferring electromagnetic energy to implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Definitions
- the present invention relates generally to an implantable device for supporting a lumenal passageway and, also, delivering, in vivo, bioactive compounds. More particularly, the present invention relates to an implantable device equipped with cantilever controls for automated delivery of bioactive compounds in response to a predetermined physiological event.
- Occlusive diseases, disorders or trauma cause patent body lumens to narrow and restrict the flow or passage of fluid or materials through the body lumen.
- occlusive disease is arteriosclerosis in which portions of blood vessels become occluded by the gradual build-up of arteriosclerotic plaque, this process is also known as stenosis.
- vascular stenosis results in the functional occlusion of a blood vessel the vessel must be returned to its patent condition.
- Conventional therapies for treatment of occluded body lumens include dilatation of the body lumen using bioactive agents, such as tissue plasminogen activator (TPA) or vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) gene transfers which have improved blood flow and collateral development in ischemic limb and myocardium (S. Yla-Herttuala, Cardiovascular gene therapy , Lancet, Jan. 15, 2000), surgical intervention to remove the blockage, replacement of the blocked segment with a new segment of endogenous or exogenous graft tissue, or the use of a catheter-mounted device such as a balloon catheter to dilate the body lumen or an artherectomy catheter to remove occlusive material.
- bioactive agents such as tissue plasminogen activator (TPA) or vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) gene transfers which have improved blood flow and collateral development in ischemic limb and myocardium (S. Yla-Hertt
- a balloon catheter in a deflated state is inserted within an occluded segment of a blood vessel and is inflated and deflated a number of times to expand the vessel. Due to the inflation of the balloon catheter, the plaque formed on the vessel walls cracks and the vessel expands to allow increased blood flow through the vessel.
- endoluminal stents While the use of endoluminal stents has successfully decreased the rate of restenosis in angioplasty patients, it has been found that a significant restenosis rate continues to exist even with the use of endoluminal stents. It is generally believed that the post-stenting restenosis rate is due, in major part, to a failure of the endothelial layer to regrow over the stent and the incidence of smooth muscle cell-related neointimal growth on the luminal surfaces of the stent. Damage to the endothelium, the natural nonthrombogenic lining of the arterial lumen, is a significant factor contributing to restenosis at the situs of a stent.
- Endothelial loss exposes thrombogenic arterial wall proteins, which, along with the generally thrombogenic nature of many prosthetic materials, such as stainless steel, titanium, tantalum, Nitinol, etc. customarily used in manufacturing stents, initiates platelet deposition and activation of the coagulation cascade, which results in thrombus formation, ranging from partial covering of the luminal surface of the stent to an occlusive thrombus. Additionally, endothelial loss at the site of the stent has been implicated in the development of neointimal hyperplasia at the stent situs.
- bioactive agents it has been found desirable to deliver bioactive agents to the area where a stent is placed concurrently with stent implantation.
- Many stents have been designed to delivery bioactive agents to the anatomical region of stent implantation. Some of these stents are biodegradable stents which are impregnated with bioactive agents. Examples of biodegradable impregnated stents are those found in U.S. Pat. Nos. 5,500,013, 5,429,634, and 5,443,458.
- Other known bioactive agent delivery stents include a stent disclosed in U.S. Pat. No. 5,342,348 in which a bioactive agent is impregnated into filaments which are woven into or laminated onto a stent.
- U.S. Pat. No. 5,234,456 discloses a hydrophilic stent that may include a bioactive agent adsorbed which can include a biologically active agent disposed within the hydrophilic material of the stent.
- Other bioactive agent delivery stents disclosed in U.S. Pat. Nos. 5,201,778, 5,282,823, 5,383,927; 5,383,928, 5,423,885, 5,441,515, 5,443,496, 5,449,382, 4,464,450, and European Patent Application No. 0 528 039.
- Other devices for endoluminal delivery of bioactive agents are disclosed in U.S. Pat. Nos.
- a directional release bioactive agent stent is disclosed in U.S. Patent No. 6,071,305 in which a stent is formed of a helical member that has a groove in the abluminal surface of the helical member. A bioactive agent is loaded into the groove prior to endoluminal delivery and the bioactive agent is therefore in direct apposition to the tissue that the bioactive agent treats.
- WO 00/18327 discloses a drug delivery stent in which a tubular conduit is wound into a helical stent.
- the tubular conduit has either a single continuous lumen or dual continuous lumens that extend the entire length of the conduit.
- the tubular conduit has regions or segments thereof that has pores to permit drug “seepage” from the conduit.
- One end of the tubular conduit is in fluid flow communication with a fluid delivery catheter, which introduces a fluid, such as drug into the continuous lumen and through the pores.
- the polymers cause an immune inflammatory response once the drug is eluted out of the polymer.
- a polymer is employed as the bioactive agent carrier, it is, therefore, desirable to isolate the polymer from body tissues in order to limit the immune inflammatory response after the bioactive agent has eluted as can be accomplished with the embodiments disclosed herein.
- an implantable medical device that can support a physiological lumen and automatically deliver a bioactive agent upon need, the need defined by a significant physiological event. More specifically, there is a need for an implantable medical device that allows for controlled delivery of a bioactive agent. Also, there is a further need for an implantable medical device that can detect a significant physiological event and can be manually activated to deliver a bioactive agent in a noninvasive manner.
- the implantable medical device is deliverable within an anatomical passageway and is capable of restoring and maintaining patency of the anatomical passageway and delivering a bioactive agent within the anatomical passageway.
- a common use for the implantable medical device is as a coronary or other vascular stent device which is percutanteously delivered to a situs within the body's vascular system using catheter-based approaches and, once implanted at the desired situs, is capable of releasing a bioactive agent to facilitate and promote a healing response within damaged or injured regions of the vasculature.
- the implantable medical device is adapted to deliver the bioactive agent in response to either an endogenous condition or conditions or an exogenous condition or conditions.
- endogenous conditions which may initiate drug delivery include, without limitation, certain physiological conditions such as growth of non-endothelial cells on the device, inflammatory responses, vascular wall pressure or the presence of T-cells or natural killer cells.
- exogenous conditions which may initiation drug delivery include applied RF fields, magnetic fields, electromagnetic fields, ultrasound, x-ray, positron emissions, and laser or photon emissions.
- a structural body preferably a generally tubular member, having at least one internal chamber or cavity within the structural body and a plurality of openings passing through the structural body and communicating between an external wall surface of the structural body and the at least one internal chamber.
- a plurality of cantilever members are provided on or are formed in a wall surface of the structural body and are positioned such that each cantilever member is superimposed over and covering at least one of the plurality of openings.
- the plurality of cantilever members consist generally of flap-like members which are preferably fabricated of shape memory or superelastic material, and have binary functionality, i.e., are either in an open or a close position.
- Each of the plurality of cantilever members may be MEMS (micro-electromechanical systems) devices responsive to defined stimulus, such as temperature or pressure, and may be derivitized by attachment of reactive moieties having binding affinity for specific biochemical markers.
- each of the cantilever members have binary functionality. In a first or closed position the cantilever members covers and occludes at least one associated opening that passes through the wall of the structural body an communicates with the internal chamber or cavity retaining the bioactive agent within the structural body.
- the cantilever In the second or open position, the cantilever deflects and uncovers the opening or openings with which it is associated, thereby permitting the bioactive agent to elute from the opening or openings.
- the second or open position of the cantilever occurs as a result of either the presence or absence of a pre-determined stimulus.
- the second position may be responsive to flow pressure, such as blood flow, such that cessation or diminution of blood flow resulting from tissue growth or occlusion, activates the second position.
- the second position may be responsive to temperature such that thermal induction, such as that induced by ultrasound resonance, may activate the second position.
- elution of the bioactive agent from the internal chamber or cavity and out of the uncovered plurality of openings may occur through a number of mechanisms, including, without limitation, free flow, pumped or pulsed flow, osmotic-mediated diffusion, capillary diffusion, displacement flow or the like.
- bioactive agent is intended to include one or more pharmacologically active compounds which may be in combination with pharmaceutically acceptable carriers and, optionally, additional ingredients such as antioxidants, stabilizing agents, permeation enhancers, and the like.
- additional ingredients such as antioxidants, stabilizing agents, permeation enhancers, and the like.
- pharmacologically active agents and bioactive agent as used herein are used synonymously with “drug(s)”.
- bioactive agents which may be used include but are not limited to antiviral drugs, antibiotic drugs, steroids, fibronectin, anti-clotting drugs, anti-platelet function drugs, drugs which prevent smooth muscle cell growth on inner surface wall of vessel, heparin, heparin fragments, aspirin, coumadin, tissue plasminogen activator (TPA), urokinase, hirudin, streptokinase, antiproliferative agents such as methotrexate, cisplatin, fluorouracil, ADRIAMYCIN, antioxidants such as ascorbic acid, beta carotene, vitamin E, antimetabolites, thromboxane inhibitors, non-steroidal and steroidal anti-inflammatory drugs, immunosuppresents, beta and calcium channel blockers, genetic materials including DNA and RNA fragments, complete expression genes, antibodies, lymphokines, growth factors, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), prostaglandins, leuk
- a further aspect of the present invention is the provision of a diametrically changeable structural member.
- the structural member may assume a cylindrical, tubular, planar, spherical, curvilinear or other general shape which is desired and suited for a particular implant application.
- an endoluminal stent that is made of a plurality of interconnected members commonly referred to struts or circumferential rings that define a generally tubular shape for the endoluminal stent. At least some of the plurality of interconnected members are fabricated in such a manner as to have least one internal cavity defined within or on the interconnected members or their interconnection members and at least one opening which communicates between the internal cavity and external the stent.
- Implantable devices contemplated by the present invention include, without limitation, covered stents, stent-grafts, grafts, heart valves, venous valves, filters, occlusion devices, catheters, osteal implants, implantable contraceptives, implantable anti-tumor pellets or rods, or other implantable medical devices.
- a stent for delivery of bioactive agents which consists, in general, of a plurality of structural elements, at least some of which have internal cavities that retain the bioactive agents, and openings that pass between the internal cavities and the surface of the structural elements to communicate the bioactive agent from the internal cavity to external the stent.
- the present invention does not depend upon the particular geometry, material, material properties or configuration of the stent.
- sensors that may be incorporated onto the implantable medical device, or more specifically, onto the cantilever, to monitor or detect either an endogenous or exogenous stimulus.
- the endogenous stimulus will, typically, be a physiological event, such as smooth muscle cell proliferation, endothelialization, plaque formation, biochemical changes, cell or cell surface protein binding, or the like.
- the sensors are preferably fabricated via thin film vacuum deposition, either as a monolithic monolayer of material or a multilayered film, wherein at least portions of the film are capable of sensing at least one of changes in fluid flow, fluid flow rate, temperature, pressure, or the presence or absence of chemical or biochemical species in the body by mechanical, electrical, chemical, electrochemical or electromechanical means.
- the sensors allow the monitoring of clinically significant physiological events based upon physical, chemical or electrical energy differences present in a body passageway.
- the sensors of the embodiments disclosed herein may be employed to sense significant changes to blood flow volume, blood flow rate, pressure, electrical energy, biochemical interactions, temperature, or to the degree and type of deposits within the lumen of an endoluminal implant, such as a stent or other type of endoluminal conduit.
- the embodiments disclosed herein also provides a means to modulate mechanical and/or physical properties of the endoluminal implant in response to the sensed or monitored parameter.
- the implantable medical device such as a stent
- the implantable medical device may be triggered to release a selected bioactive agent, whether automatically or manually controlled.
- the sensors allow for monitoring the environment around the implantable device to detect stimuli indicative of predetermined events.
- the sensors are fabricated onto or in association with the plurality of cantilever members. Upon detecting the particular event, a signal can be delivered towards the implantable device that then triggers the cantilever to undergo transformation from the closed to open position. Upon transformation, the selected bioactive agent can is released into the local environment.
- the sensors also detect the predetermined stimulus, but instead of simply monitoring, the sensor signals or transfers energy to the cantilever causing the cantilever to undergo a physical transformation from the closed to open position.
- the cantilever is fabricated to act as the sensor itself so that once the cantilever detects the energy contributing event, the cantilever responds to the energy contributing event and undergoes physical transformation from the closed to open position.
- the inventive sensor comprises at least one region of the implantable endoluminal device that is formed of a plurality of cantilever members having different mechanical properties, such as different modulus of elasticity, plasticity or stress-strain behaviors.
- the cantilever members are preferably fabricated of a superelastic material.
- the superelastic cantilever members may be positioned on either a fluid contacting or tissue contacting surface of the implantable device, such as the luminal surface of a stent which contacts blood, or on the abluminal surface of a stent which contacts neointimal tissue of the blood vessel.
- the sensors may be positioned on both the fluid contacting and the tissue-contacting surface of the implantable device.
- the superelastic cantilever sensors are responsive to changes in force, such as shear forces, applied to the sensors.
- each of the plurality of cantilever members have first and second positions that are indicative of either a closed or open position, respectively.
- the first or “closed” position of each cantilever members is coplanar or flush with the surface of the endoluminal device into which the sensor is positioned.
- each activated cantilever members projects outwardly from the surface of the endoluminal device into which the sensor is positioned.
- cantilever members or groups of cantilever members are fabricated to have either different transition temperatures or different stress-strain properties, individual cantilever members or groups of cantilever members which are in the second or “open” position, are indicative of a given thermal or stress-strain condition existing within the body into which the endoluminal device is implanted and allows for the release of bioactive agent housed in the internal cavities.
- the inventive endoluminal device comprises a temperature sensor having a plurality of cantilever members positioned on at least one of the proximal, distal or intermediate regions of the endoluminal device and positioned on at least one of the luminal or abluminal wall surfaces of the endoluminal device.
- a plurality of groups of cantilever members are provided, each group is formed of a plurality of individual cantilever members, with each individual cantilever members in the group having identical transition temperatures.
- the plurality of groups of cantilever members are arrayed along the longitudinal axis of the endoluminal device in such a manner as to create a continuum of groups of cantilever members having different transition temperatures.
- Changes in temperature at the site of the endoluminal device are indicated by the position of the cantilever members or groups of cantilever members as determined by radiography, ultrasonography, magnetic resonance imaging or other means that provides a detectable image of the position of the cantilever members and groups of cantilever members.
- the senor comprises a plurality of cantilever members positioned on at least one of the proximal, distal or intermediate regions of the endoluminal device and positioned on at least one of the luminal or abluminal wall surfaces of the endoluminal device.
- a plurality of groups of cantilever members are provided, each group is formed of a plurality of individual cantilever members, with each individual cantilever members in the group having identical transition temperatures.
- the plurality of groups of cantilever members are arrayed along the longitudinal axis of the endoluminal device in such a manner as to create a continuum of groups of cantilever members having different stress-strain transition pressures.
- Changes in applied stress or strain, such as blood pressure or blood flow shear stress, at the site of the endoluminal device are indicated by the stress and strain acting on the cantilever members or groups of cantilever members which provides a corresponding frequency shift in energy reflected, when compared to a baseline stress-strain for unloaded cantilever members.
- the position and frequency shift of the cantilever members may be determined by radiography, ultrasonography, magnetic resonance imaging or other means which provides a detectable image of the position of the individual cantilever members and groups of cantilever members or is capable of measuring frequency shifts due to differential stress-strain loading onto the cantilever members.
- the inventive sensor is a biosensor that is microfabricated from a material capable of undergoing elastic, plastic, shape-memory or superelastic deformation, and has a plurality of cantilever members formed therein, as described above.
- Each of the plurality of cantilever members has at least one binding domain selective for at least one indicator of endothelialization selected from the group of endothelial cell surface proteins, antigens, antibodies, cytokines, growth factors, co-factors, or other biological or biochemical marker of endothelial cells or endothelial cell precursors.
- Binding of the at least one indicator to at least one of the plurality of cantilever members causes a change in strain applied to the cantilever members, thereby causing the relevant cantilever members or groups of cantilever members to undergo superelastic transformation from the first or “closed” position to the second or “open” position.
- the position of the sensor cantilever members in the second or “open” position relative to the endoluminal device is indicative of the progress of endothelialization and allows for release of bioactive agents housed in the internal cavities.
- the fact of or the progress of atherosclerotic plaque formation may be sensed and treated with the appropriate bioactive agent by using a plurality of elastic or superelastic cantilever members.
- the plurality of superelastic cantilever members undergo martensitic transformation as a result of the strain applied to the cantilever members resulting from growth of atherosclerotic plaque onto the cantilever members.
- the plurality of superelastic cantilever members has at least one binding domain selective for at least one indicator of atherosclerotic plaque or its precursors.
- Binding of the atherosclerotic plaque or precursors of atherosclerotic plaque to the binding domain on the cantilever members adds a quantum of strain to the cantilever members sufficient to cause the cantilever members to undergo superelastic transformation from the first or “closed” position to the second or “open” position.
- the position of the sensor cantilever members in the second or “open” position relative to the endoluminal device is indicative of the progress of arteriosclerosis and results in the release of the appropriate bioactive agent housed in the internal cavities.
- stents Because of their use as a structural scaffold and the requirement that stents be delivered using transcatheter approaches, stents necessarily are delivered in a reduced diametric state and are expanded or allowed to expand in vivo to an enlarged diametric state. Thus, all stents have certain structural regions that are subject to higher stress and strain conditions than other structural regions of the stent. Thus, it may be advantageous to position the internal cavities that retain the bioactive agents in structural regions of the stent that are subjected to relatively lower stress and strain during endoluminal delivery and deployment. Alternatively, where delivery of a bolus of a bioactive agent is desired, internal cavities may be positioned in regions that undergo large deformation during delivery and deployment thereby forcing the bioactive agent out of the internal cavity under the positive pressure exerted by the deformation.
- FIG. 1 is a perspective view of an implantable member having a plurality of cantilever members in accordance with the embodiments disclosed herein.
- FIG. 2 is a fragmentary plan view taken from area 2 of FIG. 1 .
- FIG. 3 is a cross-sectional view taken along line 3 - 3 of FIG. 2 illustrating the a plurality of cantilever members in a first or closed position.
- FIG. 4 is the same cross-sectional view as in FIG. 3 , illustrating the plurality of cantilever members in a second or open position.
- FIG. 5 is a cross-sectional view taken along line 5 - 5 of FIG. 1 .
- FIG. 6 is a cross-sectional view of an alternate embodiment of embodiments disclosed herein.
- FIG. 7 is a fragmentary plan view of a drug-eluting stent in accordance with a preferred embodiment of the embodiments disclosed herein.
- FIG. 8 is a photomicrograph of a transverse section of a drug-eluting stent in accordance with a preferred embodiment of the embodiments disclosed herein.
- FIGS. 9A-9G are sequential cross-sectional views illustrating the method of fabricating the inventive drug eluting implantable medical device in accordance with the embodiments disclosed herein.
- the drug-eluting device 10 of the embodiments disclosed herein consists generally of a body element 12 , which for purposes of illustration only, is depicted in a generally tubular conformation having a first wall surface 14 and a second wall surface 16 , a first end surface 13 and an opposing second end surface 15 .
- a plurality of openings 20 pass through either or both of the first wall surface 14 and the second wall surface 16 and communicate between at least one chamber 21 , shown in phantom, which resides entirely within the z-axis thickness of the drug-eluting device 10 and is defined between the first wall surface 14 and the second wall surface 16 with only at least one of the plurality of openings 20 communicating between the internal chamber 21 and either the first 14 or second 16 wall surface of the drug-eluting device 10 .
- a plurality of cover members 18 are provided in or in association with either or both of the first wall surface 14 and the second wall surface 16 , and are positioned such that at least one of the plurality of openings 20 are covered by one of the plurality of cover members 18 .
- the plurality of openings 29 and the associated plurality of cover members 18 may, optionally, be arrayed in a pattern of groupings 23 a - 23 e of openings 20 and cover members 18 .
- Each of the plurality of cover members 18 have generally binary functionality in that they have a first or closed position where the associated at least one opening 20 is covered and occluded by the cover member 18 , and a second or open position where the associated at least one opening 20 is uncovered by the cover member 18 . Transition between the first position and the second position preferably occurs by either shape memory or superelastic phase transitions in the material used to fabricate the plurality of openings 20 .
- the binary transition of the plurality of cover members 18 may be synchronous or asynchronous.
- all of the plurality of cover members 18 may transition between the first to the second position under common conditions and, therefore, act synchronously; alternatively, either individual cover members 18 or groups of cover members, but not all cover members 18 , may transition under common conditions, while other cover members 18 do not undergo a binary transition, therefore, acting asynchronously.
- drug-eluting device 10 of the embodiments disclosed herein is illustrated and will be described with reference to a generally tubular embodiment, those of ordinary skill in the art will understand and appreciate that alternate geometric conformations are contemplated and feasible, including, without limitation, spherical, ovoid, planar, curvilinear or cylindrical conformations.
- the plurality of cover members 18 comprise cantilever-like members fabricated of shape memory or superelastic metal or pseudometal material.
- the cantilever-like cover members 18 may be formed as integral components in the first wall surface 14 , the second wall surface 16 , or both, may be formed as a layer upon the first wall surface 14 , the second wall surface 16 or both, or, alternatively, may be discrete members which may be coupled to the first wall surface 14 , the second wall surface 16 , or both. Further, the cantilever-like cover members may be provided in regular or irregular pattern arrays.
- the cantilever 15 can cover any or all openings 14 in any desired pattern.
- the plurality of openings 20 may have no associated cantilever-like cover member 18 , or all of the plurality of openings 20 may have associated cantilever-like cover members 18 .
- the plurality of openings 20 have dimensions sufficient to permit the bioactive agent to elute by diffusion, osmotic pressure or under the influence of a positive pressure applied by cellular in-growth into the at least one interior chamber 21 .
- FIGS. 3 and 4 illustrate the binary functioning of the plurality of cantilever-like cover members 18 .
- the plurality of cantilever-like cover members 18 are formed integrally in wall surface 14 , and each of the plurality of cantilever-like cover members 18 subtend an associated opening 20 which underlies the cover member 18 .
- openings 20 and cover members 18 could also be formed in and associated with opposing wall surface 16 .
- the interior chamber 21 is defined entirely within the Z-axis thickness of the device 10 and intermediate the first wall surface 14 and the second wall surface 16 .
- An elutable bioactive agent 24 is retained with the interior chamber 21 .
- FIG. 3 illustrates the plurality of cantilever-like cover members 18 in their first or closed position where each of the plurality of cantilever-like cover members 18 are in co-planar relationship with one another along wall surface 14 .
- FIG. 4 illustrates the plurality of cantilever cover members 18 in their second or open position where each of the plurality of cantilever-like cover members are deformed to uncover each associated opening 20 , and permit elution of the bioactive agent 24 from the interior chamber 21 and through the openings 20 .
- FIGS. 3 and 4 depict synchronous function of the plurality of cantilever-like cover members 18
- the plurality of cantilever-like cover members 18 may function asynchronously.
- FIG. 5 is a transverse cross-sectional view taken along line 5 - 5 of FIG. 1 and illustrates the drug-eluting implantable device 30 in an embodiment consisting of a generally tubular member 32 , which may be a cylindrical stent, or may be an individual strut of a stent.
- the tubular member 32 has at least one of a plurality of internal chambers 34 formed entirely between a first wall surface 14 and a second wall surface 16 of the tubular member 32 which act as a reservoir for a bioactive agent 36 .
- a central lumen 31 provides a fluid flow channel for bodily fluids to traverse the device 30 .
- the tubular member 32 may be an individual strut of a stent
- the central lumen 32 may serve as the internal chambers 34 for retaining the bioactive agent 36 to be eluted from the device 30
- the plurality of internal chambers 24 may, optionally, be eliminated.
- the plurality of openings 38 communicate between the at least one of a plurality of internal chambers 34 , the central lumen 31 and external the device 30 .
- the plurality of cantilever-like cover members 42 are formed in an outer circumferential layer 40 which forms the first wall surface 14 of device 30 .
- FIG. 6 is a transverse cross-section view of an alternate embodiment of the invention depicted in FIG. 5 .
- the alternative embodiment of the drug-eluting device 45 depicted in FIG. 6 is substantially similar to that in FIG. 5 , with the exception that the plurality of openings 47 communicate between the plurality of interior chambers 43 and central lumen 31 of the device 45 .
- the plurality of cantilever-like members 48 are formed in a lumenal layer of material 46 and cover the plurality of openings 47 to control elution of the bioactive agent 36 from the interior chambers 43 .
- the bioactive agent 36 when at least some of the plurality of cantilever-like cover members 42 transition from their first, closed position to their second, open position, the bioactive agent 36 is eluted abluminally from the device 30 , while in FIG. 6 , the bioactive agent 36 is eluted luminally from the device 45 .
- each of the plurality of openings 20 may vary dependent upon the particular indication or application for which the drug-eluting implantable device 10 is intended.
- the plurality of openings 20 may open to either a luminal wall surface 16 of the device 10 , or to an abluminal wall surface 14 of the device 10 , or both the luminal wall surface 16 and the abluminal wall surface 14 of the device 10 .
- As an alternative to having a uniform distribution of openings 20 about the circumferential and longitudinal axes of the device 10 there may be provided a higher density of openings 20 toward a proximal or distal end of the device 10 .
- a higher density of openings 20 may be provided along an intermediate region o the device 10 . It will be understood that where there is provided a higher density of openings 20 , a larger dosage of the bioactive agent 36 may be released at any one time due to the higher density of openings 20 .
- the plurality of internal chambers 34 , 41 may be either continuous or discontinuous within the z-axis thickness of the device 10 and may be present in different circumferential or longitudinal regions of the device 10 . Where discontinuous internal chambers 34 , 41 are provided, plural bioactive agents may be loaded into the device 10 for either synchronous or asynchronous elution.
- differential drug delivery may be accomplished based upon occurrence of different physiological conditions.
- the body element 12 is preferably fabricated of a biocompatible metal such as titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof, such as zirconium-titanium-tantalum alloys, nickel-titanium alloy, chromium-cobalt alloy or stainless steel.
- the plurality of cantilever-like cover members 18 are preferably fabricated of a shape memory or superelastic material, such as nickel-titanium or chromium cobalt alloy.
- Each of the plurality of cantilevers 18 may be fabricated of a material capable of undergoing elastic, plastic, shape memory and/or a superelastic deformation.
- Materials such as stainless steel, titanium, nickel, tantalum, gold, vanadium, nickel-titanium, or alloys thereof may be employed to fabricate the plurality of cantilever members.
- Different electrical, thermal or mechanical properties may be imparted to the cantilevers 18 by altering the alloy ratios of the material. It is preferable to vacuum deposit both the body element 12 and cantilevers 18 to permit tight control over the material composition, electrical, mechanical and thermal properties of the material, as well as provide for tight control over the tissue and fluid contacting surfaces and the bulk material of the device.
- the titanium content of the target, in a nickel-titanium binary target may be changed a known amount to precisely alter the transition temperature of a cantilever members 18 .
- either or both of the body member 12 and the plurality of cantilevers 18 are fabricated of thin metallic films.
- thin metallic film or “metal thin film” are used synonymously to refer to biocompatible materials made of metallic or pseudometallic materials.
- the inventive thin metallic films may be fabricated by conventional wrought metal processing techniques, or may be made by nanofabrication techniques such as physical vapor deposition or chemical vapor deposition.
- Such thin metallic films as are used with the embodiments disclosed herein may be comprised of single or plural layer films fabricated of biocompatible metals or biocompatible pseudometals having thicknesses greater than 0 ⁇ m and less than about 125 ⁇ m.
- Each of the plurality of cantilevers 18 preferably have binary functionality to provide a first “closed” position indicative of an austenite phase of the cantilevers 18 and a second “open” position indicative of a martensite phase of the cantilevers 18 .
- the closed position is configured such that it is in a lowered position that is substantially co-planar with the surface.
- the open position is configured such that it is in the raised position or projecting outwardly relative to the surface.
- the plurality of cantilever-like cover members 18 function as sensors in that they may be fabricated to sense and respond to changes in a physiological state, such as pressure, temperature, cell or protein binding, the presence or absence of a given biochemical marker, or the like. Alternatively, the plurality of cantilever-like cover members 18 may be fabricated to respond only to a specific externally applied stimulus. In this manner, an exogenous stimulus, such as a magnetic field, RF energy, ultrasound, heat or the like may be applied to actuate at least some of the plurality of cantilever-like cover members 18 and permit elution o the bioactive agent.
- a physiological state such as pressure, temperature, cell or protein binding, the presence or absence of a given biochemical marker, or the like.
- an exogenous stimulus such as a magnetic field, RF energy, ultrasound, heat or the like may be applied to actuate at least some of the plurality of cantilever-like cover members 18 and permit elution o the bioactive agent.
- ordered arrays, generally denoted as element 23 of cantilever like cover members 18 may form sensor groups, such that, for example, a cantilever-like cover members 18 forming a first array 23 a may be fabricated to have a martensitic stress/strain transition coefficient a, while cantilever-like cover members 18 forming second array 23 b are fabricated to have a transition coefficient ⁇ +1, cantilever-like cover members 18 forming a third array 23 c are fabricated to have a transition coefficient of ⁇ +2, etc. such that different cover members 18 or groups of cover members 18 change their position based upon a given quantum of stress or strain applied to the cantilever-like cover members 18 in vivo.
- each of the plurality of cover members 18 may have a response curve which is dependent upon the modulus of the material and the moment of inertia of each cantilever member. This response curve allows for varying degrees of impedance of the openings as the cover members 18 gradually shift from a closed to opening position, thereby, resulting in varying elution profiles through the openings.
- Each of the cover members 18 may be configured to have a variation in Z-axis thickness along an X-Y axis of the cover members 18 .
- different cover members 18 or different groupings of cover members 18 will exhibit different stress-strain responses due to the different material modulus and different moment of inertia attendant to the altered geometry of the cover members 18 .
- the cover members 18 will deflect and shift a returned resonance frequency applied from an external energy source. The degree of deflection will then correlate to the stress and strain forces acting upon the cover members 18 . It will be understood, of course, that this alternate construct of the cover members 18 still provides binary “closed” and “open” functionality with the “closed” and “open” positions merely being indicative of the outlying positions of the cover members 18 .
- each of the above-described preferred embodiments may be fabricated by a number of methods.
- either forming wrought metal parts, such as capillary tubing, into the implantable device or forming the implantable devices by vacuum deposition techniques are the preferred method of making the implantable structural elements of the embodiments disclosed herein.
- pre-existing microtubular members having an outer diameter, for example, between 60 and 400 ⁇ m and a wall thickness of between 10 and 350 ⁇ m, may be employed to fabricate extremely small dimensioned devices suitable for intracranial or coronary artery applications.
- the microtubular members may be formed into a cylindrical endoluminal device, such as by braiding or bending and joining microtubular members together by spot welding. Where ends of the microtubular members are formed to be self-cannulating, the self-cannulating ends may be exposed on the abluminal surface of an endoluminal device at any point along the longitudinal axis thereof.
- the plurality of openings passing through the wall of each of the individual tubular elements may be formed by microdrilling the openings through the wall and into the internal cavity or lumen of the individual tubular members.
- the plurality of openings may be laser cut, etched or formed by EDM methods, and may be formed either pre- or post-formation of the tubular elements into the three-dimensional conformation of the implantable device.
- vacuum deposition techniques may be employed to form the implantable structural body, such as sputtering, reactive ion etching, chemical vapor deposition, plasma vapor deposition, or the like, as are known in the microelectronics fabrication arts and are more fully described in commonly assigned U.S. Pat. No. 6,379,383, issued Apr. 30, 2002 and commonly assigned U.S. patent application Ser. No. 10/211,489, published as U.S. Published
- the internal chambers, the plurality of openings and the cover members may each be formed during deposition.
- the vacuum deposition process may be modified requisite patterns of sacrificial material to form the regions of the internal chambers and openings, over a base layer of structural material, then depositing a second layer of structural material over the sacrificial material and the base layer.
- the sacrificial material may then be removed, such as by etching, to leave the internal cavities and plurality of openings formed within the deposited bulk material.
- the plurality of cover members may be formed by depositing a layer of cover material, then defining the cover members in the layer of cover material, such as by laser etching to define the cantilever-like cover members in the cover material.
- FIGS. 7 and 8 illustrate an exemplary drug-delivery stent 50 in accordance with the embodiments disclosed herein, which is depicted without the covering members 18 for purposes of clarity.
- Stent 50 is comprised generally of a plurality of structural elements 52 interconnected at a plurality of hinge regions 54 and defining a plurality of interstices 56 bounded by the plurality of structural elements and the plurality of hinge regions 54 .
- the material used to fabricate the inventive device has a Z-axis wall thickness in the device material.
- the inventive device 50 incorporates at least one of a plurality of internal cavities 56 within the wall thickness of the material used to form the implantable device or endoluminal stent 50 .
- the plurality of internal cavities 56 are preferably positioned in the plurality of structural elements 52 and are preferably not present in the hinge regions 54 .
- a plurality of micropores 58 are provided and communicate between a external surface of the device 50 and one of the plurality of internal cavities 56 .
- the plurality of micropores 58 are dimensioned to permit the bioactive agent to elute from the at least one of a plurality of internal cavities 56 and through the associated plurality of micropores 58 by diffusion, osmotic pressure or under the influence of a positive pressure applied by cellular in-growth into the plurality of internal cavities 56 or under positive pressure applied by stress and/or strain exerted on the plurality of internal cavities 56 due to deformation of the individual structural elements 52 .
- the plurality of micropores 58 may furthermore be provided to communicate between an internal cavity 56 and either a luminal or abluminal surface of the inventive endoluminal stent, such as to expose the bioactive agent retained within the plurality of internal cavities 56 either to the blood stream, in the case of luminal micropores 58 , and/or to adjacent tissue, in the case of abluminal micropores 58 .
- the at least one of a plurality of internal cavities 56 may be continuous or discontinuous throughout the inventive device 50 .
- the plurality of internal cavities 56 is discontinuous and each of the plurality of discontinuous internal cavities 56 reside within regions of the device 50 that are substantially non-load bearing regions of the device.
- the plurality of hinge regions 54 are devoid of internal cavities 56 because they are load bearing regions of the stent.
- regions of the inventive device 50 that are deformed or that are load bearing may include either continuous internal cavities 56 or discontinuous internal cavities within their wall thickness and provide for elution of a bioactive agent retained within the internal cavity positioned at the load bearing region under the influence of a positive motivating pressure exerted on the bioactive agent by deformation or load stress transferred by the device geometry to the internal cavity and to the bioactive agent.
- regions of continuous and discontinuous internal cavities 56 a plurality of bioactive agents may be loaded into different internal cavities 56 for achieving different elution rates and pharmacological effects.
- FIG. 8 is a photomicrograph illustrating a transverse cross-sectional view through an individual structural element 52 illustrating the internal cavity 56 and the construction of the structural element 53 in which there is a base layer of material and a cap-layer of material overlaying and enclosing the base layer to form the internal cavity 56 .
- FIGS. 9A through 9G An exemplary method 60 for making the inventive drug-eluting medical device of the embodiments disclosed herein is illustrated, sequentially, in FIGS. 9A through 9G .
- a substrate 62 is provided; a first layer of biocompatible material 64 is deposited onto the substrate 62 , followed by a sacrificial material layer 66 .
- the following step entails patterning the sacrificial material layer 66 to leave patterned sections 68 of the sacrificial layer 66 .
- the pattern sections 68 will, as described hereinafter, form the internal chambers 21 of the inventive device.
- a second layer of biocompatible material 70 is then deposited onto the patterned sections 68 and the first layer of biocompatible material 64 as illustrated in FIG. 9C .
- a plurality of openings 72 are formed in the second layer of biocompatible material 70 and communicate with the patterned sections 68 of the sacrificial material layer 66 .
- the sacrificial material remaining in the patterned sections 68 is removed through the openings 72 to leave interior chambers 72 bounded entirely by the second layer of biocompatible material 70 and the first layer of biocompatible material 64 .
- a third layer of biocompatible material 76 is then provided to cover the second layer of biocompatible material 70 and the plurality of openings 72 therein, as illustrated in FIG.
- This third layer of biocompatible material 76 may have been preformed with a plurality of cantilever members 78 having separation gaps 80 between adjacent cantilever members 78 and adhesion regions 82 formed between the gap 80 and the opening 72 which the cantilever member 78 covers, as illustrated in FIG. 9G .
- the third layer of biocompatible material may be provided as a discrete layer of material or may consist of a plurality of individual cantilever members 78 each coupled to the second layer of biocompatible material 70 at adhesion regions 82 .
- the third biocompatible material 76 may be deposited directly onto the second layer of biocompatible material 70 , then the plurality of individual cantilever members 78 formed, such as by laser cutting or selective etching.
- the bioactive agent must be loaded into the internal cavities of the implantable device.
- Loading of the bioactive agent may be accomplished by flowing a liquid or semi-liquid state of the bioactive agent through the plurality of openings and into the internal cavities, either throughout the entire device or in regions of the implantable device.
- Flow loading may be facilitated by applying positive pressure, temperature change or both, such as is used in hot isostatic pressing (HIP).
- HIP hot isostatic pressing
- the pressurizing medium is typically a gas, and the process is carried out at elevated temperatures for specific time periods.
- HIP is typically utilized to densify materials, to heal casting defects and voids, or to bond similar or dissimilar materials it may be used to drive a fluid or semi-fluid from external the implantable device into the internal cavities of the implantable device.
- Alternative, diffusion-mediated loading, osmotic loading or vacuum loading may be employed to load the bioactive agent into the internal cavities.
Abstract
Description
- This application is a divisional of U.S. patent application Ser. No. 10/936,884, filed Sep. 9, 2004, now U.S. Pat. No. 9,407,605, which is a continuation-in-part of commonly assigned and co-pending U.S. patent applications Ser. Nos. 09/783,633, filed Feb. 14, 2001, now U.S. Pat. No. 8,372,139; Ser. No. 09/716,146, filed Nov. 17, 2000, now U.S. Pat. No. 8,252,044; and Ser. No. 10/258,087, filing date of Aug. 19, 2003, all of which are herein incorporated by reference in their entireties.
- The present invention relates generally to an implantable device for supporting a lumenal passageway and, also, delivering, in vivo, bioactive compounds. More particularly, the present invention relates to an implantable device equipped with cantilever controls for automated delivery of bioactive compounds in response to a predetermined physiological event.
- Occlusive diseases, disorders or trauma cause patent body lumens to narrow and restrict the flow or passage of fluid or materials through the body lumen. One example of occlusive disease is arteriosclerosis in which portions of blood vessels become occluded by the gradual build-up of arteriosclerotic plaque, this process is also known as stenosis. When vascular stenosis results in the functional occlusion of a blood vessel the vessel must be returned to its patent condition. Conventional therapies for treatment of occluded body lumens include dilatation of the body lumen using bioactive agents, such as tissue plasminogen activator (TPA) or vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) gene transfers which have improved blood flow and collateral development in ischemic limb and myocardium (S. Yla-Herttuala, Cardiovascular gene therapy, Lancet, Jan. 15, 2000), surgical intervention to remove the blockage, replacement of the blocked segment with a new segment of endogenous or exogenous graft tissue, or the use of a catheter-mounted device such as a balloon catheter to dilate the body lumen or an artherectomy catheter to remove occlusive material. The dilation of a blood vessel with a balloon catheter is called percutaneous transluminal angioplasty. During angioplasty, a balloon catheter in a deflated state is inserted within an occluded segment of a blood vessel and is inflated and deflated a number of times to expand the vessel. Due to the inflation of the balloon catheter, the plaque formed on the vessel walls cracks and the vessel expands to allow increased blood flow through the vessel.
- In approximately sixty percent of angioplasty cases, the blood vessel remains patent. However, the restenosis rate of approximately forty percent is unacceptably high. Endoluminal stents of a wide variety of materials, properties and configurations have been used post-angioplasty in order to prevent restenosis and loss of patency in the vessel.
- While the use of endoluminal stents has successfully decreased the rate of restenosis in angioplasty patients, it has been found that a significant restenosis rate continues to exist even with the use of endoluminal stents. It is generally believed that the post-stenting restenosis rate is due, in major part, to a failure of the endothelial layer to regrow over the stent and the incidence of smooth muscle cell-related neointimal growth on the luminal surfaces of the stent. Injury to the endothelium, the natural nonthrombogenic lining of the arterial lumen, is a significant factor contributing to restenosis at the situs of a stent. Endothelial loss exposes thrombogenic arterial wall proteins, which, along with the generally thrombogenic nature of many prosthetic materials, such as stainless steel, titanium, tantalum, Nitinol, etc. customarily used in manufacturing stents, initiates platelet deposition and activation of the coagulation cascade, which results in thrombus formation, ranging from partial covering of the luminal surface of the stent to an occlusive thrombus. Additionally, endothelial loss at the site of the stent has been implicated in the development of neointimal hyperplasia at the stent situs. Accordingly, rapid re-endothelialization of the arterial wall with concomitant endothelialization of the body fluid or blood contacting surfaces of the implanted device is considered critical for maintaining vasculature patency and preventing low-flow thrombosis. To prevent restenosis and thrombosis in the area where angioplasty has been performed, anti-thrombosis agents and other biologically active agents can be employed.
- It has been found desirable to deliver bioactive agents to the area where a stent is placed concurrently with stent implantation. Many stents have been designed to delivery bioactive agents to the anatomical region of stent implantation. Some of these stents are biodegradable stents which are impregnated with bioactive agents. Examples of biodegradable impregnated stents are those found in U.S. Pat. Nos. 5,500,013, 5,429,634, and 5,443,458. Other known bioactive agent delivery stents include a stent disclosed in U.S. Pat. No. 5,342,348 in which a bioactive agent is impregnated into filaments which are woven into or laminated onto a stent. U.S. Pat. No. 5,234,456 discloses a hydrophilic stent that may include a bioactive agent adsorbed which can include a biologically active agent disposed within the hydrophilic material of the stent. Other bioactive agent delivery stents disclosed in U.S. Pat. Nos. 5,201,778, 5,282,823, 5,383,927; 5,383,928, 5,423,885, 5,441,515, 5,443,496, 5,449,382, 4,464,450, and European Patent Application No. 0 528 039. Other devices for endoluminal delivery of bioactive agents are disclosed in U.S. Pat. Nos. 3,797,485, 4,203,442, 4,309,776, 4,479,796, 5,002,661, 5,062,829, 5,180,366, 5,295,962, 5,304,121, 5,421,826, and International Application No. WO 94/18906. A directional release bioactive agent stent is disclosed in U.S. Patent No. 6,071,305 in which a stent is formed of a helical member that has a groove in the abluminal surface of the helical member. A bioactive agent is loaded into the groove prior to endoluminal delivery and the bioactive agent is therefore in direct apposition to the tissue that the bioactive agent treats. Finally, International Application No. WO 00/18327 discloses a drug delivery stent in which a tubular conduit is wound into a helical stent. The tubular conduit has either a single continuous lumen or dual continuous lumens that extend the entire length of the conduit. The tubular conduit has regions or segments thereof that has pores to permit drug “seepage” from the conduit. One end of the tubular conduit is in fluid flow communication with a fluid delivery catheter, which introduces a fluid, such as drug into the continuous lumen and through the pores.
- Where biodegradable or non-biodegradable polymer-based or polymer-coated stents have been used, the polymers cause an immune inflammatory response once the drug is eluted out of the polymer. Where a polymer is employed as the bioactive agent carrier, it is, therefore, desirable to isolate the polymer from body tissues in order to limit the immune inflammatory response after the bioactive agent has eluted as can be accomplished with the embodiments disclosed herein.
- There still remains a need for an implantable medical device that can support a physiological lumen and automatically deliver a bioactive agent upon need, the need defined by a significant physiological event. More specifically, there is a need for an implantable medical device that allows for controlled delivery of a bioactive agent. Also, there is a further need for an implantable medical device that can detect a significant physiological event and can be manually activated to deliver a bioactive agent in a noninvasive manner.
- The implantable medical device is deliverable within an anatomical passageway and is capable of restoring and maintaining patency of the anatomical passageway and delivering a bioactive agent within the anatomical passageway. While not limiting the embodiments disclosed herein, a common use for the implantable medical device is as a coronary or other vascular stent device which is percutanteously delivered to a situs within the body's vascular system using catheter-based approaches and, once implanted at the desired situs, is capable of releasing a bioactive agent to facilitate and promote a healing response within damaged or injured regions of the vasculature.
- More particularly, the implantable medical device is adapted to deliver the bioactive agent in response to either an endogenous condition or conditions or an exogenous condition or conditions. For example, endogenous conditions which may initiate drug delivery include, without limitation, certain physiological conditions such as growth of non-endothelial cells on the device, inflammatory responses, vascular wall pressure or the presence of T-cells or natural killer cells. Non-limiting examples of exogenous conditions which may initiation drug delivery include applied RF fields, magnetic fields, electromagnetic fields, ultrasound, x-ray, positron emissions, and laser or photon emissions.
- In accordance with one embodiment, there is provided a structural body, preferably a generally tubular member, having at least one internal chamber or cavity within the structural body and a plurality of openings passing through the structural body and communicating between an external wall surface of the structural body and the at least one internal chamber. A plurality of cantilever members are provided on or are formed in a wall surface of the structural body and are positioned such that each cantilever member is superimposed over and covering at least one of the plurality of openings.
- The plurality of cantilever members consist generally of flap-like members which are preferably fabricated of shape memory or superelastic material, and have binary functionality, i.e., are either in an open or a close position. Each of the plurality of cantilever members may be MEMS (micro-electromechanical systems) devices responsive to defined stimulus, such as temperature or pressure, and may be derivitized by attachment of reactive moieties having binding affinity for specific biochemical markers. As noted, each of the cantilever members have binary functionality. In a first or closed position the cantilever members covers and occludes at least one associated opening that passes through the wall of the structural body an communicates with the internal chamber or cavity retaining the bioactive agent within the structural body. In the second or open position, the cantilever deflects and uncovers the opening or openings with which it is associated, thereby permitting the bioactive agent to elute from the opening or openings. The second or open position of the cantilever occurs as a result of either the presence or absence of a pre-determined stimulus. For example, the second position may be responsive to flow pressure, such as blood flow, such that cessation or diminution of blood flow resulting from tissue growth or occlusion, activates the second position. Alternatively, the second position may be responsive to temperature such that thermal induction, such as that induced by ultrasound resonance, may activate the second position.
- After the cantilever members assume their open position, elution of the bioactive agent from the internal chamber or cavity and out of the uncovered plurality of openings may occur through a number of mechanisms, including, without limitation, free flow, pumped or pulsed flow, osmotic-mediated diffusion, capillary diffusion, displacement flow or the like.
- As used herein the term “bioactive agent” is intended to include one or more pharmacologically active compounds which may be in combination with pharmaceutically acceptable carriers and, optionally, additional ingredients such as antioxidants, stabilizing agents, permeation enhancers, and the like. The terms “pharmacologically active agents” and “bioactive agent” as used herein are used synonymously with “drug(s)”. Examples of bioactive agents which may be used include but are not limited to antiviral drugs, antibiotic drugs, steroids, fibronectin, anti-clotting drugs, anti-platelet function drugs, drugs which prevent smooth muscle cell growth on inner surface wall of vessel, heparin, heparin fragments, aspirin, coumadin, tissue plasminogen activator (TPA), urokinase, hirudin, streptokinase, antiproliferative agents such as methotrexate, cisplatin, fluorouracil, ADRIAMYCIN, antioxidants such as ascorbic acid, beta carotene, vitamin E, antimetabolites, thromboxane inhibitors, non-steroidal and steroidal anti-inflammatory drugs, immunosuppresents, beta and calcium channel blockers, genetic materials including DNA and RNA fragments, complete expression genes, antibodies, lymphokines, growth factors, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), prostaglandins, leukotrienes, laminin, elastin, collagen, nitric oxide (NO), integrins, paclitaxel, taxol, rapamycin, rapamycin derivatives, such as those disclosed in U.S. Patent Application Publication 2003/0170287 published Sep. 11, 2003, sirolimus, rapamune, tacrolimus, dexamethasone, everolimus, ABT-578 (a rapamycin analogue that inhibits the mTOR cell cycle regulatory protein), and growth factors, such as VEG-F.
- A further aspect of the present invention is the provision of a diametrically changeable structural member. The structural member may assume a cylindrical, tubular, planar, spherical, curvilinear or other general shape which is desired and suited for a particular implant application. For example, in accordance with the present invention there is provided an endoluminal stent that is made of a plurality of interconnected members commonly referred to struts or circumferential rings that define a generally tubular shape for the endoluminal stent. At least some of the plurality of interconnected members are fabricated in such a manner as to have least one internal cavity defined within or on the interconnected members or their interconnection members and at least one opening which communicates between the internal cavity and external the stent. Alternate types of implantable devices contemplated by the present invention include, without limitation, covered stents, stent-grafts, grafts, heart valves, venous valves, filters, occlusion devices, catheters, osteal implants, implantable contraceptives, implantable anti-tumor pellets or rods, or other implantable medical devices.
- In one aspect of the present invention, there exists a stent for delivery of bioactive agents, which consists, in general, of a plurality of structural elements, at least some of which have internal cavities that retain the bioactive agents, and openings that pass between the internal cavities and the surface of the structural elements to communicate the bioactive agent from the internal cavity to external the stent. Other than described herein, the present invention does not depend upon the particular geometry, material, material properties or configuration of the stent.
- Another aspect of the embodiments disclosed herein relates to sensors that may be incorporated onto the implantable medical device, or more specifically, onto the cantilever, to monitor or detect either an endogenous or exogenous stimulus. The endogenous stimulus will, typically, be a physiological event, such as smooth muscle cell proliferation, endothelialization, plaque formation, biochemical changes, cell or cell surface protein binding, or the like. The sensors are preferably fabricated via thin film vacuum deposition, either as a monolithic monolayer of material or a multilayered film, wherein at least portions of the film are capable of sensing at least one of changes in fluid flow, fluid flow rate, temperature, pressure, or the presence or absence of chemical or biochemical species in the body by mechanical, electrical, chemical, electrochemical or electromechanical means.
- Specifically, the sensors allow the monitoring of clinically significant physiological events based upon physical, chemical or electrical energy differences present in a body passageway. For example, the sensors of the embodiments disclosed herein may be employed to sense significant changes to blood flow volume, blood flow rate, pressure, electrical energy, biochemical interactions, temperature, or to the degree and type of deposits within the lumen of an endoluminal implant, such as a stent or other type of endoluminal conduit. The embodiments disclosed herein also provides a means to modulate mechanical and/or physical properties of the endoluminal implant in response to the sensed or monitored parameter. For example, where the monitored blood flow volume through an endoluminal device is determined to be below physiological norms and/or the blood pressure is determined to be above physiological norms, the implantable medical device, such as a stent, may be triggered to release a selected bioactive agent, whether automatically or manually controlled.
- In one aspect of the invention, the sensors allow for monitoring the environment around the implantable device to detect stimuli indicative of predetermined events. In a preferred aspect, the sensors are fabricated onto or in association with the plurality of cantilever members. Upon detecting the particular event, a signal can be delivered towards the implantable device that then triggers the cantilever to undergo transformation from the closed to open position. Upon transformation, the selected bioactive agent can is released into the local environment.
- In another aspect of the invention, the sensors also detect the predetermined stimulus, but instead of simply monitoring, the sensor signals or transfers energy to the cantilever causing the cantilever to undergo a physical transformation from the closed to open position. Preferably, the cantilever is fabricated to act as the sensor itself so that once the cantilever detects the energy contributing event, the cantilever responds to the energy contributing event and undergoes physical transformation from the closed to open position.
- In accordance with another embodiment of the invention, the inventive sensor comprises at least one region of the implantable endoluminal device that is formed of a plurality of cantilever members having different mechanical properties, such as different modulus of elasticity, plasticity or stress-strain behaviors. In accordance with the best mode presently contemplated for the invention, the cantilever members are preferably fabricated of a superelastic material. As with the shape-memory cantilever members, the superelastic cantilever members may be positioned on either a fluid contacting or tissue contacting surface of the implantable device, such as the luminal surface of a stent which contacts blood, or on the abluminal surface of a stent which contacts neointimal tissue of the blood vessel. Alternatively, the sensors may be positioned on both the fluid contacting and the tissue-contacting surface of the implantable device. Unlike the shape-memory cantilever sensors, the superelastic cantilever sensors are responsive to changes in force, such as shear forces, applied to the sensors.
- With both the shape-memory cantilever members sensor and the superelastic cantilever members sensor, each of the plurality of cantilever members have first and second positions that are indicative of either a closed or open position, respectively. The first or “closed” position of each cantilever members is coplanar or flush with the surface of the endoluminal device into which the sensor is positioned. In the second or “open” position, each activated cantilever members projects outwardly from the surface of the endoluminal device into which the sensor is positioned. Because different cantilever members or groups of cantilever members are fabricated to have either different transition temperatures or different stress-strain properties, individual cantilever members or groups of cantilever members which are in the second or “open” position, are indicative of a given thermal or stress-strain condition existing within the body into which the endoluminal device is implanted and allows for the release of bioactive agent housed in the internal cavities.
- In one particular form of the invention, the inventive endoluminal device comprises a temperature sensor having a plurality of cantilever members positioned on at least one of the proximal, distal or intermediate regions of the endoluminal device and positioned on at least one of the luminal or abluminal wall surfaces of the endoluminal device. To facilitate ease of detection, a plurality of groups of cantilever members are provided, each group is formed of a plurality of individual cantilever members, with each individual cantilever members in the group having identical transition temperatures. The plurality of groups of cantilever members are arrayed along the longitudinal axis of the endoluminal device in such a manner as to create a continuum of groups of cantilever members having different transition temperatures. Changes in temperature at the site of the endoluminal device are indicated by the position of the cantilever members or groups of cantilever members as determined by radiography, ultrasonography, magnetic resonance imaging or other means that provides a detectable image of the position of the cantilever members and groups of cantilever members.
- In another particular form the invention, the sensor comprises a plurality of cantilever members positioned on at least one of the proximal, distal or intermediate regions of the endoluminal device and positioned on at least one of the luminal or abluminal wall surfaces of the endoluminal device. To facilitate ease of detection, a plurality of groups of cantilever members are provided, each group is formed of a plurality of individual cantilever members, with each individual cantilever members in the group having identical transition temperatures. The plurality of groups of cantilever members are arrayed along the longitudinal axis of the endoluminal device in such a manner as to create a continuum of groups of cantilever members having different stress-strain transition pressures. Changes in applied stress or strain, such as blood pressure or blood flow shear stress, at the site of the endoluminal device are indicated by the stress and strain acting on the cantilever members or groups of cantilever members which provides a corresponding frequency shift in energy reflected, when compared to a baseline stress-strain for unloaded cantilever members. The position and frequency shift of the cantilever members may be determined by radiography, ultrasonography, magnetic resonance imaging or other means which provides a detectable image of the position of the individual cantilever members and groups of cantilever members or is capable of measuring frequency shifts due to differential stress-strain loading onto the cantilever members.
- In yet another form of the invention, the inventive sensor is a biosensor that is microfabricated from a material capable of undergoing elastic, plastic, shape-memory or superelastic deformation, and has a plurality of cantilever members formed therein, as described above. Each of the plurality of cantilever members has at least one binding domain selective for at least one indicator of endothelialization selected from the group of endothelial cell surface proteins, antigens, antibodies, cytokines, growth factors, co-factors, or other biological or biochemical marker of endothelial cells or endothelial cell precursors. Binding of the at least one indicator to at least one of the plurality of cantilever members causes a change in strain applied to the cantilever members, thereby causing the relevant cantilever members or groups of cantilever members to undergo superelastic transformation from the first or “closed” position to the second or “open” position. As with the above-described embodiments of the invention, the position of the sensor cantilever members in the second or “open” position relative to the endoluminal device is indicative of the progress of endothelialization and allows for release of bioactive agents housed in the internal cavities.
- Similarly, the fact of or the progress of atherosclerotic plaque formation may be sensed and treated with the appropriate bioactive agent by using a plurality of elastic or superelastic cantilever members. In accordance with a first embodiment, the plurality of superelastic cantilever members undergo martensitic transformation as a result of the strain applied to the cantilever members resulting from growth of atherosclerotic plaque onto the cantilever members. In accordance with a second embodiment, the plurality of superelastic cantilever members has at least one binding domain selective for at least one indicator of atherosclerotic plaque or its precursors. Binding of the atherosclerotic plaque or precursors of atherosclerotic plaque to the binding domain on the cantilever members, adds a quantum of strain to the cantilever members sufficient to cause the cantilever members to undergo superelastic transformation from the first or “closed” position to the second or “open” position. As with the above-described embodiments of the invention, the position of the sensor cantilever members in the second or “open” position relative to the endoluminal device is indicative of the progress of arteriosclerosis and results in the release of the appropriate bioactive agent housed in the internal cavities.
- Because of their use as a structural scaffold and the requirement that stents be delivered using transcatheter approaches, stents necessarily are delivered in a reduced diametric state and are expanded or allowed to expand in vivo to an enlarged diametric state. Thus, all stents have certain structural regions that are subject to higher stress and strain conditions than other structural regions of the stent. Thus, it may be advantageous to position the internal cavities that retain the bioactive agents in structural regions of the stent that are subjected to relatively lower stress and strain during endoluminal delivery and deployment. Alternatively, where delivery of a bolus of a bioactive agent is desired, internal cavities may be positioned in regions that undergo large deformation during delivery and deployment thereby forcing the bioactive agent out of the internal cavity under the positive pressure exerted by the deformation.
- Diffusion forces, then, elute remaining bioactive agent present in either the region of large deformation or the regions of lower stress and strain.
-
FIG. 1 is a perspective view of an implantable member having a plurality of cantilever members in accordance with the embodiments disclosed herein. -
FIG. 2 is a fragmentary plan view taken fromarea 2 ofFIG. 1 . -
FIG. 3 is a cross-sectional view taken along line 3-3 ofFIG. 2 illustrating the a plurality of cantilever members in a first or closed position. -
FIG. 4 is the same cross-sectional view as inFIG. 3 , illustrating the plurality of cantilever members in a second or open position. -
FIG. 5 is a cross-sectional view taken along line 5-5 ofFIG. 1 . -
FIG. 6 is a cross-sectional view of an alternate embodiment of embodiments disclosed herein. -
FIG. 7 is a fragmentary plan view of a drug-eluting stent in accordance with a preferred embodiment of the embodiments disclosed herein. -
FIG. 8 is a photomicrograph of a transverse section of a drug-eluting stent in accordance with a preferred embodiment of the embodiments disclosed herein. -
FIGS. 9A-9G are sequential cross-sectional views illustrating the method of fabricating the inventive drug eluting implantable medical device in accordance with the embodiments disclosed herein. - With particular reference to
FIGS. 1 and 2 , the drug-elutingdevice 10 of the embodiments disclosed herein consists generally of abody element 12, which for purposes of illustration only, is depicted in a generally tubular conformation having afirst wall surface 14 and asecond wall surface 16, afirst end surface 13 and an opposingsecond end surface 15. A plurality ofopenings 20 pass through either or both of thefirst wall surface 14 and thesecond wall surface 16 and communicate between at least onechamber 21, shown in phantom, which resides entirely within the z-axis thickness of the drug-elutingdevice 10 and is defined between thefirst wall surface 14 and thesecond wall surface 16 with only at least one of the plurality ofopenings 20 communicating between theinternal chamber 21 and either the first 14 or second 16 wall surface of the drug-elutingdevice 10. A plurality ofcover members 18 are provided in or in association with either or both of thefirst wall surface 14 and thesecond wall surface 16, and are positioned such that at least one of the plurality ofopenings 20 are covered by one of the plurality ofcover members 18. The plurality of openings 29 and the associated plurality ofcover members 18 may, optionally, be arrayed in a pattern ofgroupings 23 a-23 e ofopenings 20 andcover members 18. Each of the plurality ofcover members 18 have generally binary functionality in that they have a first or closed position where the associated at least oneopening 20 is covered and occluded by thecover member 18, and a second or open position where the associated at least oneopening 20 is uncovered by thecover member 18. Transition between the first position and the second position preferably occurs by either shape memory or superelastic phase transitions in the material used to fabricate the plurality ofopenings 20. The binary transition of the plurality ofcover members 18 may be synchronous or asynchronous. That is, that all of the plurality ofcover members 18 may transition between the first to the second position under common conditions and, therefore, act synchronously; alternatively, eitherindividual cover members 18 or groups of cover members, but not allcover members 18, may transition under common conditions, whileother cover members 18 do not undergo a binary transition, therefore, acting asynchronously. - While the drug-eluting
device 10 of the embodiments disclosed herein is illustrated and will be described with reference to a generally tubular embodiment, those of ordinary skill in the art will understand and appreciate that alternate geometric conformations are contemplated and feasible, including, without limitation, spherical, ovoid, planar, curvilinear or cylindrical conformations. - In accordance with a preferred embodiment of the embodiments disclosed herein, the plurality of
cover members 18 comprise cantilever-like members fabricated of shape memory or superelastic metal or pseudometal material. The cantilever-like cover members 18 may be formed as integral components in thefirst wall surface 14, thesecond wall surface 16, or both, may be formed as a layer upon thefirst wall surface 14, thesecond wall surface 16 or both, or, alternatively, may be discrete members which may be coupled to thefirst wall surface 14, thesecond wall surface 16, or both. Further, the cantilever-like cover members may be provided in regular or irregular pattern arrays. Thecantilever 15 can cover any or allopenings 14 in any desired pattern. Additionally, some of the plurality ofopenings 20 may have no associated cantilever-like cover member 18, or all of the plurality ofopenings 20 may have associated cantilever-like cover members 18. The plurality ofopenings 20 have dimensions sufficient to permit the bioactive agent to elute by diffusion, osmotic pressure or under the influence of a positive pressure applied by cellular in-growth into the at least oneinterior chamber 21. -
FIGS. 3 and 4 illustrate the binary functioning of the plurality of cantilever-like cover members 18. In the embodiments illustrated inFIGS. 3 and 4 , the plurality of cantilever-like cover members 18 are formed integrally inwall surface 14, and each of the plurality of cantilever-like cover members 18 subtend an associatedopening 20 which underlies thecover member 18. Those skilled in the art will appreciate thatopenings 20 andcover members 18 could also be formed in and associated with opposingwall surface 16. Theinterior chamber 21 is defined entirely within the Z-axis thickness of thedevice 10 and intermediate thefirst wall surface 14 and thesecond wall surface 16. An elutablebioactive agent 24 is retained with theinterior chamber 21.FIG. 3 illustrates the plurality of cantilever-like cover members 18 in their first or closed position where each of the plurality of cantilever-like cover members 18 are in co-planar relationship with one another alongwall surface 14.FIG. 4 illustrates the plurality ofcantilever cover members 18 in their second or open position where each of the plurality of cantilever-like cover members are deformed to uncover each associatedopening 20, and permit elution of thebioactive agent 24 from theinterior chamber 21 and through theopenings 20. As noted above, whileFIGS. 3 and 4 depict synchronous function of the plurality of cantilever-like cover members 18, the plurality of cantilever-like cover members 18 may function asynchronously. -
FIG. 5 is a transverse cross-sectional view taken along line 5-5 ofFIG. 1 and illustrates the drug-elutingimplantable device 30 in an embodiment consisting of a generallytubular member 32, which may be a cylindrical stent, or may be an individual strut of a stent. Thetubular member 32 has at least one of a plurality ofinternal chambers 34 formed entirely between afirst wall surface 14 and asecond wall surface 16 of thetubular member 32 which act as a reservoir for abioactive agent 36. Acentral lumen 31 provides a fluid flow channel for bodily fluids to traverse thedevice 30. Alternatively, where thetubular member 32 may be an individual strut of a stent, thecentral lumen 32 may serve as theinternal chambers 34 for retaining thebioactive agent 36 to be eluted from thedevice 30, in which case, the plurality ofinternal chambers 24 may, optionally, be eliminated. The plurality ofopenings 38 communicate between the at least one of a plurality ofinternal chambers 34, thecentral lumen 31 and external thedevice 30. The plurality of cantilever-like cover members 42 are formed in an outercircumferential layer 40 which forms thefirst wall surface 14 ofdevice 30. -
FIG. 6 is a transverse cross-section view of an alternate embodiment of the invention depicted inFIG. 5 . The alternative embodiment of the drug-elutingdevice 45 depicted inFIG. 6 is substantially similar to that inFIG. 5 , with the exception that the plurality ofopenings 47 communicate between the plurality ofinterior chambers 43 andcentral lumen 31 of thedevice 45. Additionally, the plurality of cantilever-like members 48 are formed in a lumenal layer ofmaterial 46 and cover the plurality ofopenings 47 to control elution of thebioactive agent 36 from theinterior chambers 43. Thus, inFIG. 5 , when at least some of the plurality of cantilever-like cover members 42 transition from their first, closed position to their second, open position, thebioactive agent 36 is eluted abluminally from thedevice 30, while inFIG. 6 , thebioactive agent 36 is eluted luminally from thedevice 45. - The position of each of the plurality of
openings 20 may vary dependent upon the particular indication or application for which the drug-elutingimplantable device 10 is intended. The plurality ofopenings 20 may open to either aluminal wall surface 16 of thedevice 10, or to anabluminal wall surface 14 of thedevice 10, or both theluminal wall surface 16 and theabluminal wall surface 14 of thedevice 10. As an alternative to having a uniform distribution ofopenings 20 about the circumferential and longitudinal axes of thedevice 10, there may be provided a higher density ofopenings 20 toward a proximal or distal end of thedevice 10. Alternatively, a higher density ofopenings 20 may be provided along an intermediate region o thedevice 10. It will be understood that where there is provided a higher density ofopenings 20, a larger dosage of thebioactive agent 36 may be released at any one time due to the higher density ofopenings 20. - In addition to the foregoing positioning of the plurality of
openings 21, the plurality ofinternal chambers device 10 and may be present in different circumferential or longitudinal regions of thedevice 10. Where discontinuousinternal chambers device 10 for either synchronous or asynchronous elution. - By employing asynchronous functioning plurality of cantilever-
like cover members 18, differential drug delivery may be accomplished based upon occurrence of different physiological conditions. - The
body element 12 is preferably fabricated of a biocompatible metal such as titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof, such as zirconium-titanium-tantalum alloys, nickel-titanium alloy, chromium-cobalt alloy or stainless steel. The plurality of cantilever-like cover members 18 are preferably fabricated of a shape memory or superelastic material, such as nickel-titanium or chromium cobalt alloy. - Each of the plurality of
cantilevers 18 may be fabricated of a material capable of undergoing elastic, plastic, shape memory and/or a superelastic deformation. Materials such as stainless steel, titanium, nickel, tantalum, gold, vanadium, nickel-titanium, or alloys thereof may be employed to fabricate the plurality of cantilever members. Different electrical, thermal or mechanical properties may be imparted to thecantilevers 18 by altering the alloy ratios of the material. It is preferable to vacuum deposit both thebody element 12 andcantilevers 18 to permit tight control over the material composition, electrical, mechanical and thermal properties of the material, as well as provide for tight control over the tissue and fluid contacting surfaces and the bulk material of the device. For example with nickel-titanium alloys, the titanium content of the target, in a nickel-titanium binary target, may be changed a known amount to precisely alter the transition temperature of acantilever members 18. - In accordance with one embodiment either or both of the
body member 12 and the plurality ofcantilevers 18 are fabricated of thin metallic films. As used herein, the term “thin metallic film” or “metal thin film” are used synonymously to refer to biocompatible materials made of metallic or pseudometallic materials. The inventive thin metallic films may be fabricated by conventional wrought metal processing techniques, or may be made by nanofabrication techniques such as physical vapor deposition or chemical vapor deposition. - Such thin metallic films as are used with the embodiments disclosed herein may be comprised of single or plural layer films fabricated of biocompatible metals or biocompatible pseudometals having thicknesses greater than 0 μm and less than about 125 μm.
- Each of the plurality of
cantilevers 18 preferably have binary functionality to provide a first “closed” position indicative of an austenite phase of thecantilevers 18 and a second “open” position indicative of a martensite phase of thecantilevers 18. The closed position is configured such that it is in a lowered position that is substantially co-planar with the surface. On the other hand, the open position is configured such that it is in the raised position or projecting outwardly relative to the surface. - It will be understood, therefore, that as the implanted temperature sensor encounters different in vivo temperatures, different sets of cantilever members will be exposed to their transition temperature and change from the “closed” position to the “open” position. Once in the open position, the cantilevers do not impede elution of bioactive agents through the openings from the internal cavities.
- The plurality of cantilever-
like cover members 18 function as sensors in that they may be fabricated to sense and respond to changes in a physiological state, such as pressure, temperature, cell or protein binding, the presence or absence of a given biochemical marker, or the like. Alternatively, the plurality of cantilever-like cover members 18 may be fabricated to respond only to a specific externally applied stimulus. In this manner, an exogenous stimulus, such as a magnetic field, RF energy, ultrasound, heat or the like may be applied to actuate at least some of the plurality of cantilever-like cover members 18 and permit elution o the bioactive agent. - As illustrated in
FIG. 1 , ordered arrays, generally denoted aselement 23, of cantilever likecover members 18 may form sensor groups, such that, for example, a cantilever-like cover members 18 forming afirst array 23 a may be fabricated to have a martensitic stress/strain transition coefficient a, while cantilever-like cover members 18 formingsecond array 23 b are fabricated to have a transition coefficient σ+1, cantilever-like cover members 18 forming a third array 23 c are fabricated to have a transition coefficient of σ+2, etc. such thatdifferent cover members 18 or groups ofcover members 18 change their position based upon a given quantum of stress or strain applied to the cantilever-like cover members 18 in vivo. - Alternatively rather than having merely binary functionality, each of the plurality of
cover members 18 may have a response curve which is dependent upon the modulus of the material and the moment of inertia of each cantilever member. This response curve allows for varying degrees of impedance of the openings as thecover members 18 gradually shift from a closed to opening position, thereby, resulting in varying elution profiles through the openings. - Each of the
cover members 18 may be configured to have a variation in Z-axis thickness along an X-Y axis of thecover members 18. By configuring thecover members 18 with variable Z-axis thicknesses,different cover members 18 or different groupings ofcover members 18 will exhibit different stress-strain responses due to the different material modulus and different moment of inertia attendant to the altered geometry of thecover members 18. With this alternate construct of thecover members 18, for a given quantum of stress-strain applied to thecover members 18, thecover members 18 will deflect and shift a returned resonance frequency applied from an external energy source. The degree of deflection will then correlate to the stress and strain forces acting upon thecover members 18. It will be understood, of course, that this alternate construct of thecover members 18 still provides binary “closed” and “open” functionality with the “closed” and “open” positions merely being indicative of the outlying positions of thecover members 18. - It will be understood, therefore, that as the implanted sensor encounters different stress and strain associated with, for example, changes in physiological blood pressure, fluid shear stress, endothelialization, arterioschlerotic plaque development, different sets of cantilever members will be exposed to their transition conditions and change from the “closed” position to the “open” position.
- Each of the above-described preferred embodiments may be fabricated by a number of methods. In accordance with embodiments disclosed herein, it is contemplated that either forming wrought metal parts, such as capillary tubing, into the implantable device or forming the implantable devices by vacuum deposition techniques are the preferred method of making the implantable structural elements of the embodiments disclosed herein. Where an implantable device is to be fabricated of a plurality of individual tubular elements, pre-existing microtubular members having an outer diameter, for example, between 60 and 400 μm and a wall thickness of between 10 and 350 μm, may be employed to fabricate extremely small dimensioned devices suitable for intracranial or coronary artery applications. The microtubular members may be formed into a cylindrical endoluminal device, such as by braiding or bending and joining microtubular members together by spot welding. Where ends of the microtubular members are formed to be self-cannulating, the self-cannulating ends may be exposed on the abluminal surface of an endoluminal device at any point along the longitudinal axis thereof. The plurality of openings passing through the wall of each of the individual tubular elements may be formed by microdrilling the openings through the wall and into the internal cavity or lumen of the individual tubular members. The plurality of openings may be laser cut, etched or formed by EDM methods, and may be formed either pre- or post-formation of the tubular elements into the three-dimensional conformation of the implantable device.
- Where an implantable device is to be formed from non-preexisting structural elements, vacuum deposition techniques may be employed to form the implantable structural body, such as sputtering, reactive ion etching, chemical vapor deposition, plasma vapor deposition, or the like, as are known in the microelectronics fabrication arts and are more fully described in commonly assigned U.S. Pat. No. 6,379,383, issued Apr. 30, 2002 and commonly assigned U.S. patent application Ser. No. 10/211,489, published as U.S. Published
- Patent Application No. 20030059640 published Mar. 27, 2003, both of which are hereby incorporated by reference as teaching methods of fabrication of implantable materials using physical vapor deposition processes.
- The internal chambers, the plurality of openings and the cover members may each be formed during deposition. In order to form these elements by vacuum deposition, the vacuum deposition process may be modified requisite patterns of sacrificial material to form the regions of the internal chambers and openings, over a base layer of structural material, then depositing a second layer of structural material over the sacrificial material and the base layer. The sacrificial material may then be removed, such as by etching, to leave the internal cavities and plurality of openings formed within the deposited bulk material. The plurality of cover members may be formed by depositing a layer of cover material, then defining the cover members in the layer of cover material, such as by laser etching to define the cantilever-like cover members in the cover material.
-
FIGS. 7 and 8 illustrate an exemplary drug-delivery stent 50 in accordance with the embodiments disclosed herein, which is depicted without the coveringmembers 18 for purposes of clarity. Those of ordinary skill in the art will understand and recognize that alternative device designs and geometries are also contemplated by the embodiments disclosed herein.Stent 50 is comprised generally of a plurality ofstructural elements 52 interconnected at a plurality ofhinge regions 54 and defining a plurality ofinterstices 56 bounded by the plurality of structural elements and the plurality ofhinge regions 54. As described above, the material used to fabricate the inventive device has a Z-axis wall thickness in the device material. Theinventive device 50 incorporates at least one of a plurality ofinternal cavities 56 within the wall thickness of the material used to form the implantable device orendoluminal stent 50. The plurality ofinternal cavities 56 are preferably positioned in the plurality ofstructural elements 52 and are preferably not present in thehinge regions 54. - A plurality of
micropores 58 are provided and communicate between a external surface of thedevice 50 and one of the plurality ofinternal cavities 56. As noted above, the plurality ofmicropores 58 are dimensioned to permit the bioactive agent to elute from the at least one of a plurality ofinternal cavities 56 and through the associated plurality ofmicropores 58 by diffusion, osmotic pressure or under the influence of a positive pressure applied by cellular in-growth into the plurality ofinternal cavities 56 or under positive pressure applied by stress and/or strain exerted on the plurality ofinternal cavities 56 due to deformation of the individualstructural elements 52. The plurality ofmicropores 58 may furthermore be provided to communicate between aninternal cavity 56 and either a luminal or abluminal surface of the inventive endoluminal stent, such as to expose the bioactive agent retained within the plurality ofinternal cavities 56 either to the blood stream, in the case ofluminal micropores 58, and/or to adjacent tissue, in the case ofabluminal micropores 58. - The at least one of a plurality of
internal cavities 56 may be continuous or discontinuous throughout theinventive device 50. Specifically, in accordance with one preferred embodiment of the invention, the plurality ofinternal cavities 56 is discontinuous and each of the plurality of discontinuousinternal cavities 56 reside within regions of thedevice 50 that are substantially non-load bearing regions of the device. In the particular embodiment illustrated inFIG. 7 , the plurality ofhinge regions 54 are devoid ofinternal cavities 56 because they are load bearing regions of the stent. It is contemplated, however, that regions of theinventive device 50 that are deformed or that are load bearing may include either continuousinternal cavities 56 or discontinuous internal cavities within their wall thickness and provide for elution of a bioactive agent retained within the internal cavity positioned at the load bearing region under the influence of a positive motivating pressure exerted on the bioactive agent by deformation or load stress transferred by the device geometry to the internal cavity and to the bioactive agent. By providing regions of continuous and discontinuousinternal cavities 56, a plurality of bioactive agents may be loaded into differentinternal cavities 56 for achieving different elution rates and pharmacological effects.FIG. 8 is a photomicrograph illustrating a transverse cross-sectional view through an individualstructural element 52 illustrating theinternal cavity 56 and the construction of the structural element 53 in which there is a base layer of material and a cap-layer of material overlaying and enclosing the base layer to form theinternal cavity 56. - An
exemplary method 60 for making the inventive drug-eluting medical device of the embodiments disclosed herein is illustrated, sequentially, inFIGS. 9A through 9G . As depicted inFIG. 9A , asubstrate 62 is provided; a first layer ofbiocompatible material 64 is deposited onto thesubstrate 62, followed by asacrificial material layer 66. InFIG. 9B , the following step entails patterning thesacrificial material layer 66 to leave patternedsections 68 of thesacrificial layer 66. Thepattern sections 68 will, as described hereinafter, form theinternal chambers 21 of the inventive device. A second layer ofbiocompatible material 70 is then deposited onto thepatterned sections 68 and the first layer ofbiocompatible material 64 as illustrated inFIG. 9C . As illustrated inFIG. 9D , a plurality ofopenings 72 are formed in the second layer ofbiocompatible material 70 and communicate with thepatterned sections 68 of thesacrificial material layer 66. Then, as illustrated inFIG. 9E , the sacrificial material remaining in the patternedsections 68 is removed through theopenings 72 to leaveinterior chambers 72 bounded entirely by the second layer ofbiocompatible material 70 and the first layer ofbiocompatible material 64. A third layer ofbiocompatible material 76 is then provided to cover the second layer ofbiocompatible material 70 and the plurality ofopenings 72 therein, as illustrated inFIG. 9F . This third layer ofbiocompatible material 76 may have been preformed with a plurality ofcantilever members 78 havingseparation gaps 80 betweenadjacent cantilever members 78 andadhesion regions 82 formed between thegap 80 and theopening 72 which thecantilever member 78 covers, as illustrated inFIG. 9G . Those skilled in the art will appreciate that the third layer of biocompatible material may be provided as a discrete layer of material or may consist of a plurality ofindividual cantilever members 78 each coupled to the second layer ofbiocompatible material 70 atadhesion regions 82. The thirdbiocompatible material 76 may be deposited directly onto the second layer ofbiocompatible material 70, then the plurality ofindividual cantilever members 78 formed, such as by laser cutting or selective etching. However, it will be important to interpose a sacrificial interlayer mask which covers the secondbiocompatible layer 70 and the plurality ofopenings 72, but exposes only theadhesion regions 82 so that, after removal of the sacrificial interlayer mask, the plurality ofcantilever members 78 are free to deflect from and open the plurality ofopenings 72. - Regardless of which fabrication method is employed, the bioactive agent must be loaded into the internal cavities of the implantable device. Loading of the bioactive agent may be accomplished by flowing a liquid or semi-liquid state of the bioactive agent through the plurality of openings and into the internal cavities, either throughout the entire device or in regions of the implantable device. Flow loading may be facilitated by applying positive pressure, temperature change or both, such as is used in hot isostatic pressing (HIP). In HIP the pressurizing medium is typically a gas, and the process is carried out at elevated temperatures for specific time periods. While HIP is typically utilized to densify materials, to heal casting defects and voids, or to bond similar or dissimilar materials it may be used to drive a fluid or semi-fluid from external the implantable device into the internal cavities of the implantable device. Alternative, diffusion-mediated loading, osmotic loading or vacuum loading may be employed to load the bioactive agent into the internal cavities.
- While the present invention has been described with reference to its preferred embodiments, those of ordinary skill in the art will understand and appreciate that variations in structural materials, bioactive agents, fabrication methods, device configuration or device indication and use may be made without departing from the invention, which is limited in scope only by the claims appended hereto.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/825,526 US20150342761A1 (en) | 2000-11-17 | 2015-08-13 | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/716,146 US8252044B1 (en) | 2000-11-17 | 2000-11-17 | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US09/783,633 US8372139B2 (en) | 2001-02-14 | 2001-02-14 | In vivo sensor and method of making same |
US25808703A | 2003-08-19 | 2003-08-19 | |
US10/936,884 US9107605B2 (en) | 2000-11-17 | 2004-09-09 | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US14/825,526 US20150342761A1 (en) | 2000-11-17 | 2015-08-13 | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/936,884 Division US9107605B2 (en) | 2000-11-17 | 2004-09-09 | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150342761A1 true US20150342761A1 (en) | 2015-12-03 |
Family
ID=36037033
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/936,884 Active 2027-11-22 US9107605B2 (en) | 2000-11-17 | 2004-09-09 | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US13/589,683 Abandoned US20130166018A1 (en) | 2004-09-09 | 2012-08-20 | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US14/825,526 Abandoned US20150342761A1 (en) | 2000-11-17 | 2015-08-13 | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/936,884 Active 2027-11-22 US9107605B2 (en) | 2000-11-17 | 2004-09-09 | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US13/589,683 Abandoned US20130166018A1 (en) | 2004-09-09 | 2012-08-20 | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
Country Status (8)
Country | Link |
---|---|
US (3) | US9107605B2 (en) |
EP (1) | EP1788979A4 (en) |
JP (1) | JP2008512211A (en) |
CN (1) | CN101043859A (en) |
AU (1) | AU2005282305A1 (en) |
CA (1) | CA2577855A1 (en) |
MX (1) | MX2007002688A (en) |
WO (1) | WO2006029364A2 (en) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7736687B2 (en) * | 2006-01-31 | 2010-06-15 | Advance Bio Prosthetic Surfaces, Ltd. | Methods of making medical devices |
US8458879B2 (en) * | 2001-07-03 | 2013-06-11 | Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. | Method of fabricating an implantable medical device |
US8372139B2 (en) * | 2001-02-14 | 2013-02-12 | Advanced Bio Prosthetic Surfaces, Ltd. | In vivo sensor and method of making same |
US20060173399A1 (en) * | 2005-02-01 | 2006-08-03 | Rodgers M S | MEMS flow module with pivoting-type baffle |
US7217428B2 (en) * | 2004-05-28 | 2007-05-15 | Technology Innovations Llc | Drug delivery apparatus utilizing cantilever |
US7744642B2 (en) * | 2004-11-19 | 2010-06-29 | Biomedical Research Associates, Inc. | Prosthetic venous valves |
US20070043427A1 (en) * | 2005-08-19 | 2007-02-22 | Medlogics Device Corporation | Lumen-supporting stents |
US20070055346A1 (en) * | 2005-09-02 | 2007-03-08 | Medtronic Vascular, Inc. | Method and apparatus for delivery of a treatment element in a blood vessel |
US20070061006A1 (en) * | 2005-09-14 | 2007-03-15 | Nathan Desatnik | Methods of making shape memory films by chemical vapor deposition and shape memory devices made thereby |
US20070191816A1 (en) * | 2006-02-13 | 2007-08-16 | Boston Scientific Scimed, Inc. | Radio frequency induced drug elution |
IL178633A0 (en) * | 2006-10-16 | 2007-09-20 | Josef Flomenblit | Temperature controlled valve for regulating cooling gas flow |
EP2153802B1 (en) * | 2006-12-07 | 2011-08-03 | Mallinckrodt Inc. | Medical devices for localized drug delivery |
US7575593B2 (en) * | 2007-01-30 | 2009-08-18 | Medtronic Vascular, Inc. | Implantable device with reservoirs for increased drug loading |
WO2008134493A1 (en) * | 2007-04-25 | 2008-11-06 | Boston Scientific Scimed, Inc. | Medical devices for releasing therapeutic agent and methods of making the same |
US7922760B2 (en) * | 2007-05-29 | 2011-04-12 | Abbott Cardiovascular Systems Inc. | In situ trapping and delivery of agent by a stent having trans-strut depots |
DE102007032688A1 (en) * | 2007-07-13 | 2009-01-22 | Biotronik Vi Patent Ag | Implant and system of an implant and an excitation device |
JP2010533563A (en) | 2007-07-19 | 2010-10-28 | ボストン サイエンティフィック リミテッド | Endoprosthesis with adsorption inhibiting surface |
JP2010535541A (en) | 2007-08-03 | 2010-11-25 | ボストン サイエンティフィック リミテッド | Coating for medical devices with large surface area |
US20090076591A1 (en) * | 2007-09-19 | 2009-03-19 | Boston Scientific Scimed, Inc. | Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface |
JP5581311B2 (en) | 2008-04-22 | 2014-08-27 | ボストン サイエンティフィック サイムド,インコーポレイテッド | MEDICAL DEVICE HAVING INORGANIC MATERIAL COATING AND MANUFACTURING METHOD THEREOF |
WO2009132176A2 (en) | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
EP2403439B1 (en) | 2009-03-06 | 2016-07-20 | The Regents of The University of California | Thin film vascular stent and biocompatible surface treatment |
US20100305688A1 (en) * | 2009-05-26 | 2010-12-02 | Mallinckrodt Inc. | Medical Devices for Localized Drug Delivery |
US9283305B2 (en) | 2009-07-09 | 2016-03-15 | Medtronic Vascular, Inc. | Hollow tubular drug eluting medical devices |
US8678046B2 (en) | 2009-09-20 | 2014-03-25 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
US8828474B2 (en) | 2009-09-20 | 2014-09-09 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
US20110070358A1 (en) * | 2009-09-20 | 2011-03-24 | Medtronic Vascular, Inc. | Method of forming hollow tubular drug eluting medical devices |
US8381774B2 (en) * | 2009-09-20 | 2013-02-26 | Medtronic Vascular, Inc. | Methods for loading a drug eluting medical device |
US8696740B2 (en) * | 2010-01-05 | 2014-04-15 | The Johns Hopkins University | Implantable pressure-actuated drug delivery systems and methods of manufacture and use |
EP2384725B1 (en) * | 2010-05-06 | 2018-07-04 | Biotronik AG | Biocorrodable implant in which corrosion may be triggered or accelerated after implantation by means of an external stimulus |
EP2575675A4 (en) | 2010-05-25 | 2015-07-29 | Univ California | Ultra-low fractional area coverage flow diverter for treating aneurysms and vascular diseases |
US8333801B2 (en) | 2010-09-17 | 2012-12-18 | Medtronic Vascular, Inc. | Method of Forming a Drug-Eluting Medical Device |
US20120071961A1 (en) * | 2010-09-17 | 2012-03-22 | Medtronic Vascular, Inc. | Stent With Hollow Drug-Eluting Elements |
US8616040B2 (en) | 2010-09-17 | 2013-12-31 | Medtronic Vascular, Inc. | Method of forming a drug-eluting medical device |
US8632846B2 (en) | 2010-09-17 | 2014-01-21 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
CN102370476B (en) * | 2011-09-28 | 2013-07-10 | 上海交通大学 | Cardiovascular blood flow velocity sensor |
US10426642B2 (en) * | 2011-10-10 | 2019-10-01 | National University Of Singapore | Membrane for covering a peripheral surface of a stent |
WO2013166606A1 (en) * | 2012-05-11 | 2013-11-14 | Laboratoires Bodycad Inc. | Phantom for calibration of imaging system |
US9949692B2 (en) | 2012-12-21 | 2018-04-24 | Canary Medical Inc. | Stent graft monitoring assembly and method of use thereof |
JP5897239B1 (en) * | 2013-02-22 | 2016-03-30 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Hyperthermia for diagnostic imaging |
WO2014151906A1 (en) | 2013-03-14 | 2014-09-25 | Medtronic Vascular Inc. | Method for manufacturing a stent and stent manufactured thereby |
WO2014143750A1 (en) * | 2013-03-15 | 2014-09-18 | Boston Scientific Scimed, Inc. | Anti-migration micropatterned stent coating |
WO2014144070A1 (en) * | 2013-03-15 | 2014-09-18 | Hunter William L | Stent monitoring assembly and method of use thereof |
WO2015200718A1 (en) | 2014-06-25 | 2015-12-30 | Hunter William L | Devices, systems and methods for using and monitoring tubes in body passageways |
CN104287878B (en) * | 2014-09-16 | 2017-02-08 | 李宝童 | Blood intra-cavity support |
GB2533410B (en) * | 2014-12-19 | 2017-03-01 | Cirrus Logic Int Semiconductor Ltd | MEMS devices and processes |
EP3298416A1 (en) * | 2015-05-22 | 2018-03-28 | Ecole Polytechnique Federale de Lausanne (EPFL) | Multilayer mems cantilevers |
WO2016210380A1 (en) | 2015-06-26 | 2016-12-29 | Nsvascular, Inc. | Thin-film micromesh covers for medical devices and related methods |
EP3316827B1 (en) * | 2015-07-02 | 2023-10-11 | Monarch Biosciences, Inc. | Thin-film micromesh medical devices and related methods |
WO2017214434A1 (en) * | 2016-06-10 | 2017-12-14 | Medtronic Vascular Inc. | Drug-eluting stent formed from a deformable hollow strut for a customizable elution rate |
CN107095728A (en) * | 2017-05-19 | 2017-08-29 | 东莞颠覆产品设计有限公司 | Carried stent in tube chamber |
US10441221B2 (en) * | 2017-06-26 | 2019-10-15 | Cook Medical Technologies Llc | Graft prosthesis with pocket for microsystem |
US10939990B2 (en) * | 2017-11-28 | 2021-03-09 | Medtronic Vascular, Inc. | Graft material having selectively advanced permeability structure and method |
US11564582B2 (en) | 2017-12-15 | 2023-01-31 | Koninklijke Philips N.V. | Implant device for in-body monitoring |
KR102068887B1 (en) * | 2018-02-14 | 2020-01-21 | 인제대학교 산학협력단 | Medical anti-cancer stent unit |
WO2019195860A2 (en) | 2018-04-04 | 2019-10-10 | Vdyne, Llc | Devices and methods for anchoring transcatheter heart valve |
CN108670381B (en) * | 2018-05-25 | 2023-11-28 | 大博医疗科技股份有限公司 | Drug carrying device for bone needle implant and drug carrying method thereof |
JP7322133B2 (en) * | 2018-07-18 | 2023-08-07 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | Medical devices for shunts, occluders, fenestrations and related systems and methods |
CN108938158A (en) * | 2018-07-23 | 2018-12-07 | 上海市第人民医院 | A kind of load medicine intravascular stent based on nano-medicament carrier |
US10321995B1 (en) | 2018-09-20 | 2019-06-18 | Vdyne, Llc | Orthogonally delivered transcatheter heart valve replacement |
US10595994B1 (en) | 2018-09-20 | 2020-03-24 | Vdyne, Llc | Side-delivered transcatheter heart valve replacement |
US11278437B2 (en) | 2018-12-08 | 2022-03-22 | Vdyne, Inc. | Compression capable annular frames for side delivery of transcatheter heart valve replacement |
US11344413B2 (en) | 2018-09-20 | 2022-05-31 | Vdyne, Inc. | Transcatheter deliverable prosthetic heart valves and methods of delivery |
US11071627B2 (en) | 2018-10-18 | 2021-07-27 | Vdyne, Inc. | Orthogonally delivered transcatheter heart valve frame for valve in valve prosthesis |
US11109969B2 (en) | 2018-10-22 | 2021-09-07 | Vdyne, Inc. | Guidewire delivery of transcatheter heart valve |
US11253359B2 (en) | 2018-12-20 | 2022-02-22 | Vdyne, Inc. | Proximal tab for side-delivered transcatheter heart valves and methods of delivery |
US11273032B2 (en) | 2019-01-26 | 2022-03-15 | Vdyne, Inc. | Collapsible inner flow control component for side-deliverable transcatheter heart valve prosthesis |
US11185409B2 (en) | 2019-01-26 | 2021-11-30 | Vdyne, Inc. | Collapsible inner flow control component for side-delivered transcatheter heart valve prosthesis |
CN109602497B (en) * | 2019-02-01 | 2023-07-28 | 强企创新科技有限公司 | Puncture robot |
AU2020231221A1 (en) | 2019-03-05 | 2021-09-23 | Vdyne, Inc. | Tricuspid regurgitation control devices for orthogonal transcatheter heart valve prosthesis |
US11173027B2 (en) | 2019-03-14 | 2021-11-16 | Vdyne, Inc. | Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same |
US11076956B2 (en) | 2019-03-14 | 2021-08-03 | Vdyne, Inc. | Proximal, distal, and anterior anchoring tabs for side-delivered transcatheter mitral valve prosthesis |
CN114072106A (en) | 2019-05-04 | 2022-02-18 | 维迪内股份有限公司 | Cinching device and method for deploying a laterally delivered prosthetic heart valve in a native annulus |
CN110236748B (en) * | 2019-05-30 | 2021-03-26 | 中国人民解放军陆军军医大学第一附属医院 | Exempt from to make accurate external windowing aortic support of order |
JP2022544707A (en) | 2019-08-20 | 2022-10-20 | ブイダイン,インコーポレイテッド | Devices and methods for delivery and retrieval of laterally deliverable transcatheter valve prostheses |
JP2022545728A (en) | 2019-08-26 | 2022-10-28 | ブイダイン,インコーポレイテッド | Transcatheter prosthetic valves capable of lateral delivery and methods for their delivery and fixation |
US11234813B2 (en) | 2020-01-17 | 2022-02-01 | Vdyne, Inc. | Ventricular stability elements for side-deliverable prosthetic heart valves and methods of delivery |
CN115737892A (en) * | 2022-11-21 | 2023-03-07 | 诺莱生物医学科技有限公司 | Elastic dressing carrying repair matrix and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5061914A (en) * | 1989-06-27 | 1991-10-29 | Tini Alloy Company | Shape-memory alloy micro-actuator |
US6245444B1 (en) * | 1997-10-02 | 2001-06-12 | New Jersey Institute Of Technology | Micromachined element and method of fabrication thereof |
US20020020053A1 (en) * | 1999-12-20 | 2002-02-21 | Fonash Stephen J. | Deposited thin films and their use in separation and sacrificial layer applications |
US20020183721A1 (en) * | 2001-05-31 | 2002-12-05 | Santini John T. | Microchip devices with improved reservoir opening |
US7217428B2 (en) * | 2004-05-28 | 2007-05-15 | Technology Innovations Llc | Drug delivery apparatus utilizing cantilever |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797485A (en) * | 1971-03-26 | 1974-03-19 | Alza Corp | Novel drug delivery device for administering drug into blood circulation in blood vessel |
US4203442A (en) * | 1977-08-29 | 1980-05-20 | Alza Corporation | Device for delivering drug to a fluid environment |
US4309776A (en) * | 1980-05-13 | 1982-01-12 | Ramon Berguer | Intravascular implantation device and method of using the same |
US4525205A (en) | 1982-01-22 | 1985-06-25 | Zoecon Corporation | Herbicidal compositions comprising compounds containing a phenylaminophenoxy moiety |
US4479796A (en) * | 1982-11-15 | 1984-10-30 | Medtronic, Inc. | Self-regenerating drug administration device |
US4995863A (en) * | 1986-10-06 | 1991-02-26 | Catheter Technology Corporation | Catheter with slit valve |
NZ228382A (en) * | 1989-03-17 | 1992-08-26 | Carter Holt Harvey Plastic Pro | Drug administering coil-like device for insertion in body cavity of animal |
US5201778A (en) * | 1989-07-04 | 1993-04-13 | Giovanni Brotzu | Vascular prosthesis containing in the wall microcapsules, including hormone-producing cells |
US5002661A (en) * | 1989-08-25 | 1991-03-26 | W. R. Grace & Co.-Conn. | Artificial pancreatic perfusion device |
US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
ATE120377T1 (en) * | 1990-02-08 | 1995-04-15 | Howmedica | INFLATABLE DILATATOR. |
US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5370681A (en) * | 1991-09-16 | 1994-12-06 | Atrium Medical Corporation | Polyumenal implantable organ |
US5411550A (en) * | 1991-09-16 | 1995-05-02 | Atrium Medical Corporation | Implantable prosthetic device for the delivery of a bioactive material |
US5500013A (en) * | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5224938A (en) * | 1992-03-18 | 1993-07-06 | Strato Medical Corporation | Valved catheter |
US5282823A (en) * | 1992-03-19 | 1994-02-01 | Medtronic, Inc. | Intravascular radially expandable stent |
US5368566A (en) * | 1992-04-29 | 1994-11-29 | Cardiovascular Dynamics, Inc. | Delivery and temporary stent catheter having a reinforced perfusion lumen |
US5383927A (en) * | 1992-05-07 | 1995-01-24 | Intervascular Inc. | Non-thromogenic vascular prosthesis |
US5383928A (en) * | 1992-06-10 | 1995-01-24 | Emory University | Stent sheath for local drug delivery |
US5449382A (en) * | 1992-11-04 | 1995-09-12 | Dayton; Michael P. | Minimally invasive bioactivated endoprosthesis for vessel repair |
US5342348A (en) * | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
US5443458A (en) * | 1992-12-22 | 1995-08-22 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method of manufacture |
US5429634A (en) * | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
US5441515A (en) * | 1993-04-23 | 1995-08-15 | Advanced Cardiovascular Systems, Inc. | Ratcheting stent |
US5707385A (en) * | 1994-11-16 | 1998-01-13 | Advanced Cardiovascular Systems, Inc. | Drug loaded elastic membrane and method for delivery |
US6231600B1 (en) * | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6599275B1 (en) | 1996-06-04 | 2003-07-29 | Cook Incorporated | Implantable medical device |
GB9619856D0 (en) | 1996-09-24 | 1996-11-06 | Fotomechanix Ltd | Channel forming method |
US6099561A (en) * | 1996-10-21 | 2000-08-08 | Inflow Dynamics, Inc. | Vascular and endoluminal stents with improved coatings |
US6387121B1 (en) * | 1996-10-21 | 2002-05-14 | Inflow Dynamics Inc. | Vascular and endoluminal stents with improved coatings |
US6197013B1 (en) * | 1996-11-06 | 2001-03-06 | Setagon, Inc. | Method and apparatus for drug and gene delivery |
ZA9710342B (en) * | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
IT1289815B1 (en) | 1996-12-30 | 1998-10-16 | Sorin Biomedica Cardio Spa | ANGIOPLASTIC STENT AND RELATED PRODUCTION PROCESS |
US5843172A (en) | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US6240616B1 (en) * | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US6203536B1 (en) * | 1997-06-17 | 2001-03-20 | Medtronic, Inc. | Medical device for delivering a therapeutic substance and method therefor |
US6143370A (en) * | 1997-08-27 | 2000-11-07 | Northeastern University | Process for producing polymer coatings with various porosities and surface areas |
US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US6231516B1 (en) * | 1997-10-14 | 2001-05-15 | Vacusense, Inc. | Endoluminal implant with therapeutic and diagnostic capability |
US6273908B1 (en) * | 1997-10-24 | 2001-08-14 | Robert Ndondo-Lay | Stents |
US7713297B2 (en) * | 1998-04-11 | 2010-05-11 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US6013099A (en) * | 1998-04-29 | 2000-01-11 | Medtronic, Inc. | Medical device for delivering a water-insoluble therapeutic salt or substance |
US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
JP2000017457A (en) * | 1998-07-03 | 2000-01-18 | Shincron:Kk | Thin film forming apparatus and thin film forming method |
US6096175A (en) * | 1998-07-17 | 2000-08-01 | Micro Therapeutics, Inc. | Thin film stent |
AU771367B2 (en) * | 1998-08-20 | 2004-03-18 | Cook Medical Technologies Llc | Coated implantable medical device |
US6358276B1 (en) | 1998-09-30 | 2002-03-19 | Impra, Inc. | Fluid containing endoluminal stent |
US6471675B1 (en) * | 1999-04-30 | 2002-10-29 | Medtronic, Inc. | Passive flow control devices for implantable pumps |
US6719805B1 (en) | 1999-06-09 | 2004-04-13 | C. R. Bard, Inc. | Devices and methods for treating tissue |
US6258121B1 (en) * | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6471689B1 (en) | 1999-08-16 | 2002-10-29 | Thomas Jefferson University | Implantable drug delivery catheter system with capillary interface |
DE60032912T2 (en) | 1999-09-03 | 2007-10-25 | Advanced Cardiovascular Systems, Inc., Santa Clara | POROUS PROSTHESIS AND METHOD FOR THE DEPOSITION OF SUBSTANCES IN THE PORES |
US6287628B1 (en) * | 1999-09-03 | 2001-09-11 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
EP1229901B1 (en) * | 1999-11-17 | 2009-03-18 | Boston Scientific Limited | Microfabricated devices for the delivery of molecules into a carrier fluid |
US6537310B1 (en) * | 1999-11-19 | 2003-03-25 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable devices and method of making same |
US6471721B1 (en) * | 1999-12-30 | 2002-10-29 | Advanced Cardiovascular Systems, Inc. | Vascular stent having increased radiopacity and method for making same |
US6355063B1 (en) * | 2000-01-20 | 2002-03-12 | Impra, Inc. | Expanded PTFE drug delivery graft |
ATE499988T1 (en) * | 2000-03-02 | 2011-03-15 | Microchips Inc | MICROMECHANICAL DEVICES AND METHODS FOR STORAGE AND SELECTIVE EXPOSURE OF CHEMICALS |
EP1132058A1 (en) | 2000-03-06 | 2001-09-12 | Advanced Laser Applications Holding S.A. | Intravascular prothesis |
US6565526B2 (en) * | 2000-03-09 | 2003-05-20 | The Regents Of The University Of California | Bistable microvalve and microcatheter system |
EP1132493A3 (en) * | 2000-03-09 | 2001-09-19 | Junji Kido | Vapor deposition method of organic compound and refinement method of organic compound |
US20020013616A1 (en) * | 2000-05-05 | 2002-01-31 | Andrew Carter | Multilayer stents having enhanced flexibility and hoop strength |
US8252044B1 (en) * | 2000-11-17 | 2012-08-28 | Advanced Bio Prosthestic Surfaces, Ltd. | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US20050113798A1 (en) * | 2000-07-21 | 2005-05-26 | Slater Charles R. | Methods and apparatus for treating the interior of a blood vessel |
US8372139B2 (en) * | 2001-02-14 | 2013-02-12 | Advanced Bio Prosthetic Surfaces, Ltd. | In vivo sensor and method of making same |
US7077859B2 (en) * | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US7776029B2 (en) * | 2001-01-30 | 2010-08-17 | The Alfred E. Mann Foundation For Scientific Research | Microminiature infusion pump |
WO2002069848A2 (en) * | 2001-03-06 | 2002-09-12 | Board Of Regents, The University Of Texas System | Apparatus for stent deployment with delivery of bioactive agents |
US7445616B2 (en) * | 2001-03-23 | 2008-11-04 | Petrakis Dennis N | Temperature responsive systems |
US20050085769A1 (en) * | 2001-07-17 | 2005-04-21 | Kerberos Proximal Solutions | Fluid exchange system for controlled and localized irrigation and aspiration |
US7223282B1 (en) * | 2001-09-27 | 2007-05-29 | Advanced Cardiovascular Systems, Inc. | Remote activation of an implantable device |
US7101394B2 (en) * | 2002-05-02 | 2006-09-05 | Boston Scientific Scimed, Inc. | Energetically-controlled delivery of biologically active material from an implanted medical device |
US7500986B2 (en) * | 2002-07-11 | 2009-03-10 | Medtronic Vascular, Inc. | Expandable body having deployable microstructures and related methods |
WO2004071487A2 (en) * | 2002-08-16 | 2004-08-26 | Microchips, Inc. | Controlled release device and method |
US7172622B2 (en) * | 2002-10-30 | 2007-02-06 | Boston Scientific Scimed, Inc. | Medical devices including a magnetically activatable body or portion for treatment |
EP1560613A1 (en) | 2002-11-08 | 2005-08-10 | Conor Medsystems, Inc. | Method and apparatus for reducing tissue damage after ischemic injury |
US6902544B2 (en) * | 2003-01-22 | 2005-06-07 | Codman & Shurtleff, Inc. | Troubleshooting accelerator system for implantable drug delivery pumps |
US7235067B2 (en) * | 2003-03-06 | 2007-06-26 | Medtronic, Inc. | Sleeve valve catheters |
US7163555B2 (en) * | 2003-04-08 | 2007-01-16 | Medtronic Vascular, Inc. | Drug-eluting stent for controlled drug delivery |
US20050027350A1 (en) * | 2003-07-30 | 2005-02-03 | Biotronik Mess-Und Therapiegeraete Gmbh & Co Ingenieurbuero Berlin | Endovascular implant for the injection of an active substance into the media of a blood vessel |
AU2004273998A1 (en) * | 2003-09-18 | 2005-03-31 | Advanced Bio Prosthetic Surfaces, Ltd. | Medical device having mems functionality and methods of making same |
US7647090B1 (en) * | 2003-12-30 | 2010-01-12 | Given Imaging, Ltd. | In-vivo sensing device and method for producing same |
US8915957B2 (en) * | 2004-03-11 | 2014-12-23 | Alcatel Lucent | Drug delivery stent |
-
2004
- 2004-09-09 US US10/936,884 patent/US9107605B2/en active Active
-
2005
- 2005-09-09 CA CA002577855A patent/CA2577855A1/en not_active Abandoned
- 2005-09-09 AU AU2005282305A patent/AU2005282305A1/en not_active Abandoned
- 2005-09-09 EP EP05800213A patent/EP1788979A4/en not_active Withdrawn
- 2005-09-09 MX MX2007002688A patent/MX2007002688A/en not_active Application Discontinuation
- 2005-09-09 JP JP2007531397A patent/JP2008512211A/en active Pending
- 2005-09-09 WO PCT/US2005/032268 patent/WO2006029364A2/en active Application Filing
- 2005-09-09 CN CNA2005800297021A patent/CN101043859A/en active Pending
-
2012
- 2012-08-20 US US13/589,683 patent/US20130166018A1/en not_active Abandoned
-
2015
- 2015-08-13 US US14/825,526 patent/US20150342761A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5061914A (en) * | 1989-06-27 | 1991-10-29 | Tini Alloy Company | Shape-memory alloy micro-actuator |
US6245444B1 (en) * | 1997-10-02 | 2001-06-12 | New Jersey Institute Of Technology | Micromachined element and method of fabrication thereof |
US20020020053A1 (en) * | 1999-12-20 | 2002-02-21 | Fonash Stephen J. | Deposited thin films and their use in separation and sacrificial layer applications |
US20020183721A1 (en) * | 2001-05-31 | 2002-12-05 | Santini John T. | Microchip devices with improved reservoir opening |
US7217428B2 (en) * | 2004-05-28 | 2007-05-15 | Technology Innovations Llc | Drug delivery apparatus utilizing cantilever |
Also Published As
Publication number | Publication date |
---|---|
CA2577855A1 (en) | 2006-03-16 |
WO2006029364A3 (en) | 2006-10-19 |
CN101043859A (en) | 2007-09-26 |
EP1788979A4 (en) | 2007-11-07 |
MX2007002688A (en) | 2007-05-18 |
AU2005282305A1 (en) | 2006-03-16 |
US9107605B2 (en) | 2015-08-18 |
WO2006029364A2 (en) | 2006-03-16 |
US20050186241A1 (en) | 2005-08-25 |
US20130166018A1 (en) | 2013-06-27 |
JP2008512211A (en) | 2008-04-24 |
EP1788979A2 (en) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9107605B2 (en) | Device for in vivo delivery of bioactive agents and method of manufacture thereof | |
US20190060094A1 (en) | Endoluminal device for in vivo delivery of bioactive agents | |
US10398830B2 (en) | Device for in vivo delivery of bioactive agents and method of manufacture thereof | |
AU2002249771A1 (en) | Device for in vivo delivery of bioactive agents and method of manufacture thereof | |
EP1871439B1 (en) | Hybrid biodegradable/non-biodegradable stent, delivery system and method of treating a vascular condition | |
EP2211788B1 (en) | Stent made of wire having a spiral channel for drug delivery | |
EP1591079B1 (en) | Locking stent having multiple locking points | |
US20050149163A1 (en) | Reduced restenosis drug containing stents | |
US20050187609A1 (en) | Devices and methods for treatment of stenotic regions | |
US20090264982A1 (en) | Stent with auxiliary treatment structure | |
US20070067020A1 (en) | Intraluminal stent, delivery system, and a method of treating a vascular condition | |
US20130274687A1 (en) | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADVANCED BIO PROSTHETIC SURFACES, LTD., A WHOLLY O Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARTON, DENES;BAILEY, STEVEN R.;BANAS, CHRISTOPHER E.;SIGNING DATES FROM 20040920 TO 20040922;REEL/FRAME:036320/0550 Owner name: ADVANCED BIO PROSTHETIC SURFACES, LTD., A WHOLLY O Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOYLE, CHRISTOPHER T.;REEL/FRAME:036320/0602 Effective date: 20001117 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: VACTRONIX SCIENTIFIC, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ADVANCED BIO PROSTHETIC SURFACES, LTD., A WHOLLY OWNED SUBSIDIARY OF PALMAZ SCIENTIFIC, INC.;REEL/FRAME:045709/0763 Effective date: 20180503 |
|
AS | Assignment |
Owner name: VACTRONIX SCIENTIFIC, LLC, TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VACTRONIX SCIENTIFIC, INC.;REEL/FRAME:046203/0682 Effective date: 20180516 |